US20050170006A1 - Methods of applying a biological composition to an individual - Google Patents
Methods of applying a biological composition to an individual Download PDFInfo
- Publication number
- US20050170006A1 US20050170006A1 US11/049,010 US4901005A US2005170006A1 US 20050170006 A1 US20050170006 A1 US 20050170006A1 US 4901005 A US4901005 A US 4901005A US 2005170006 A1 US2005170006 A1 US 2005170006A1
- Authority
- US
- United States
- Prior art keywords
- plasma
- thrombin
- biological composition
- agent
- applying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3616—Batch-type treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0427—Platelets; Thrombocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
- A61M2205/331—Optical measuring means used as turbidity change detectors, e.g. for priming-blood or plasma-hemoglubine-interface detection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Definitions
- the present invention relates to autologous bioadhesive sealant compositions, and more particularly to a convenient and practical two-phase method for preparing a bioadhesive sealant specifically from blood components derived from the patient who is to receive the bioadhesive sealant.
- Blood coagulation is the result of the complex interaction of a number of protein clotting factors through a cascade ( FIG. 1 ).
- damage to the vascular endothelium exposes subendothelial structures, which attract platelets and induce them to aggregate reversibly.
- the protein thrombin, formed during activation of the coagulation pathway generates insoluble cross-linked fibrils of the protein fibrin and causes the platelets to aggregate irreversibly.
- the resulting platelet-fibrin clot is an effective barrier against loss of blood from the vascular system and also serves as a scaffold for subsequent repair of the lining of the blood vessel.
- Bioadhesive sealants and fibrin glues represent a relatively new technological advance that duplicates the biological process of the final stage of blood coagulation.
- Clinical reports document the utility of fibrin glue in a variety of surgical fields, such as, cardiovascular, thoracic, transplantation, head and neck, oral, gastrointestinal, orthopedic, neurosurgical, and plastic surgery.
- the two primary components comprising the fibrin glue, fibrinogen and thrombin, are mixed together to form a clot.
- the clot adheres to the necessary tissues, bone, or nerve within seconds, but is then slowly reabsorbed by the body in approximately 10 days by fibrinolysis.
- fibrin glue has its ability to: (1) achieve haemostasis at vascular anastomoses particularly in areas which are difficult to approach with sutures or where suture placement presents excessive risk; (2) control bleeding from needle holes or arterial tears which cannot be controlled by suturing alone; and (3) obtain haemostasis in heparinized patients or those with coagulopathy.
- coagulopathy a condition in which fibrin glue is administered.
- lipid-enveloped viruses such as HIV, associated with AIDS, cytomegalovirus (CMV), as well as Epstein-Barr virus, and the herpes simplex viruses in fibrinogen preparations make it unlikely that there will be a change in this policy in the foreseeable future.
- CMV cytomegalovirus
- Epstein-Barr virus Epstein-Barr virus
- human thrombin is also not currently authorized for human use in the United States.
- Bovine thrombin which is licensed for human use in the United States is obtained from bovine sources which do not appear to carry significant risks for HIV and hepatitis, although other bovine pathogens, such as bovine spongiform, encephalitis, may be present.
- Rose, et al. discloses a method of preparing a cryoprecipitated suspension containing fibrinogen and Factor XIII useful as a precursor in the preparation of a fibrin glue which involves (a) freezing fresh plasma from a single donor such as a human or other animal, e.g. a cow, sheep or pig, which has been screened for blood transmitted diseases, e.g. one or more of syphilis, hepatitis or acquired immune deficiency syndrome at about ⁇ 80° C. for at least about 6 hours, preferably for at least about 12 hours; (b) raising the temperature of the frozen plasma, e.g. to between about 0° C.
- a single donor such as a human or other animal, e.g. a cow, sheep or pig
- blood transmitted diseases e.g. one or more of syphilis, hepatitis or acquired immune deficiency syndrome at about ⁇ 80° C. for at least about 6 hours, preferably for at least about 12
- the fibrin glue is then prepared by applying a defined volume of the cyroprecipitate suspension described above and applying a composition containing a sufficient amount of thrombin, e.g. human, bovine, ovine or porcine thrombin, to the site so as to cause the fibrinogen in the suspension to be converted to the fibrin glue which then solidifies in the form of a gel. See U.S. Pat. No. 4,627,879.
- thrombin e.g. human, bovine, ovine or porcine thrombin
- a second technique for preparing fibrin glue is disclosed by Marx in U.S. Pat. No. 5,607,694. Essentially a cryoprecipitate as discussed previously serves as the source of the fibrinogen component and then Marx adds thrombin and liposomes.
- a fibrin glue prepared by mixing bovine thrombin not only with human coagulant proteins, such as fibrinogen, fibronectin, Factor XIII, and plasminogen, but also with bovine aprotinin and calcium chloride.
- a final disadvantage associated with the methods previously disclosed is that while human thrombin is contemplated for use as an activator, human thrombin is not available for clinical use and there is no evidence that patients will not have an antigenic response to human thrombin.
- recombinant human factor VIII has been shown to produce antigenic responses in hemophiliacs. See, Biasi, R. de., Thrombosis and Haemostasis, 71(5): 544-547 (1994). Consequently, until more clinical studies are performed on the effect of human recombinant thrombin one cannot merely assume that the use of recombinant human thrombin would obviate the antigenic problems associated with bovine thrombin.
- a second difficulty with thrombin is that it is autocatalytic, that is, it tends to self-destruct making handling and prolonged storage a problem.
- this invention provides a method for preparing a completely autologous bioadhesive sealant composition.
- This invention further provides an autologous bioadhesive sealant composition wherein the risks associated with the use of bovine and recombinant human thrombin are eliminated.
- This invention further provides an autologous bioadhesive sealant composition or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied.
- the method of this invention comprises the formation of an autologous bioadhesive sealant comprising the steps of forming a platelet rich plasma or platelet poor plasma containing an anticoagulant.
- the platelet rich plasma or platelet poor plasma is then divided into two portions and the first portion is restored so that it can coagulate, thus forming a clot.
- the clot is triturated and the resulting serum is collected.
- the bioadhesive sealant composition is then prepared by combining a defined volume of the second portion of platelet rich plasma or platelet poor plasma with a sufficient volume of serum causing the fibrinogen in the second portion of platelet rich plasma or platelet poor plasma to be converted to fibrin, which then solidifies in the form of a gel.
- FIG. 1 is a diagrammatic representation of the blood coagulation cascade.
- FIG. 2 a is a flow diagram representing the initial portion of the method of the present invention used to obtain platelet rich plasma and platelet poor plasma.
- FIG. 2 b is a flow diagram representing the final portion of the method for preparing the bioadhesive sealant composition of the present invention using platelet rich plasma as a starting material.
- FIG. 2 c is a flow diagram representing the final portion of the method for preparing the bioadhesive sealant composition of the present invention using platelet poor plasma as a starting material.
- FIG. 3 is a graphic representation of the effect that the serum-to-plasma ratio has on clotting times.
- FIG. 4 a is a graphic representation of the relationship between clotting time and actual gel time using blood drawn from a donor.
- FIG. 4 b is a graphic representation of the relationship between clotting time and actual gel time using blood drawn from a donor.
- FIG. 5 a graphically represents the effect of calcium addition on clotting times and gel times using blood drawn from a donor.
- FIG. 5 b graphically represents the effect of calcium addition on clotting times and gel times using blood drawn from a donor.
- FIG. 6 graphically represents the effect of calcium addition on the clotting times of platelet rich plasma and platelet poor plasma.
- the present invention relates to a two-phase method, shown in FIGS. 2 a , 2 b and 2 c , for forming an autologous bioadhesive sealant composition or fibrin glue wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied.
- a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient.
- the platelet rich plasma and platelet poor plasma are then divided into two portions.
- a compound that reverses the effect of the anticoagulant is added, and a clot is allowed to form.
- the clot is then triturated and the resulting serum, containing autologous thrombin, is collected.
- the serum obtained from phase-one is then mixed with the second portion of the platelet rich plasma or platelet poor plasma, used in phase-two, to form the bioadhesive sealant of the present invention.
- the method of the present invention for preparing an autologous bioadhesive composition is represented in the flow diagram depicted in FIGS. 2 a , 2 b and 2 c .
- the method of the present invention begins by forming anticoagulated whole blood 90 , which is achieved by collecting a patient's whole blood 80 in a medium containing an anticoagulation agent, such as sodium citrate (citrate) or heparin.
- an anticoagulation agent such as sodium citrate (citrate) or heparin.
- the act of drawing blood initiates clotting reactions, and unless something is done to stop the process, a clot will form.
- the formation of a clot is a multi-step process and several of these steps require the presence of calcium ions.
- a calcium chelating agent is a chemical that reacts with the calcium, present in blood, in such a fashion that the calcium can no longer function in blood coagulation.
- the most common chelating agent is a salt of citric acid (citrate), since it has the fewest side effects on the components of the clotting system.
- the whole blood 80 is collected and mixed with a 3.8% solution of sodium citrate (referred to herein as “citrate collection medium”) specifically in a 9:1 ratio of blood to citrate collection medium.
- a 3.8% solution of sodium citrate is prepared by adding 3.8 grams of sodium citrate per 100 ml of water. While a 3.8% sodium citrate collection medium is that which is frequently used to collect and preserve blood, the person skilled in this art will recognize that the ratio of sodium citrate to whole blood could be in the range of about 10.9-12.9% mMAL, final concentration.
- the anticoagulated whole blood 90 is next centrifuged at a rate of approximately 20-50 r.c.f.'s (relative centrifugal force) for 10-40 minutes, and preferably in a refrigerated centrifuge at 25 r.c.f.'s for 20 minutes, resulting in the formation of two liquid phases.
- the top phase is a platelet rich plasma (PRP) 100
- the bottom phase is anticoagulated whole blood minus the platelet rich plasma 190 .
- the platelet rich plasma (PRP) 100 is then gently drawn off and saved in a container.
- the remaining anticoagulated whole blood minus the platelet rich plasma phase 190 is further centrifuged at a rate of approximately 3000-4500 r.c.f.'s for 15-30 minutes, and preferably in a refrigerated centrifuge at 3850 r.c.f.'s for 20 minutes. This higher rate of centrifugation results in the red blood cells, white blood cells and platelets being spun out of the anticoagulated whole blood minus the platelet rich plasma phase 190 thereby forming a pellet (not shown) comprising cellular components which is to be discarded.
- the resulting platelet poor plasma (PPP) 200 is then decanted from the pellet and saved in a container.
- the containers which store the platelet rich plasma 100 and platelet poor plasma 200 , may have either wettable surfaces (such as, silica, diatomaceous earth, kaolin, etc.) or non-wettable surfaces (such as plastic, siliconized glass, etc.). Since surfaces play a role in activating blood coagulation, the surface of the container chosen to store either the platelet rich plasma 100 or the platelet poor plasma 200 is dependent on whether clot formation is desired quickly or slowly. Chemical activators, such as kaolin, can also be used to speed up the clotting time; however, their subsequent removal would also be necessary.
- a glass tube is the preferred container used to collect the platelet rich plasma 100 and the platelet poor plasma 200 .
- the platelet rich plasma 100 is divided into two portions.
- the first portion is approximately 1/4 to 1 ⁇ 2 of the total volume of platelet rich plasma 100 and is utilized in phase-one to prepare the thrombin, while the second portion of platelet rich plasma 100 is utilized in phase-two.
- the preferred methods to obtain the bioadhesive sealant compositions in an expedited manner are detailed diagrammatically in routes 101 or 201 , shown in FIGS. 2 b and 2 c , respectively and discussed in detail below.
- the method to obtain the bioadhesive sealant composition of the present invention can proceed along the routes 105 and 205 , which are also detailed diagrammatically in FIGS. 2 b and 2 c , respectively and discussed in detail below.
- Phase one begins by restoring the clot-forming process.
- an agent capable of reversing the effects of the anticoagulation agent is added back into the first portion of the platelet rich plasma 100 .
- the reversal of the anticoagulant is accomplished using calcium chloride.
- any substance that is known or found to be functionally equivalent to calcium chloride, such as, calcium gluconate, in restoring the coagulation activity of citrated blood may be used in the practice of the present invention.
- calcium chloride is the presently preferred calcium salt for use in the invention, any calcium salt which functions in a similar manner to calcium chloride may be used in the invention.
- any substance that is known or subsequently found to be functionally equivalent to calcium in facilitating these coagulation reactions may be used, either individually or in combination with calcium, in the practice of the present invention.
- the anticoagulation agent used was heparin, then heparinase would be used to reverse the effect of the anticoagulation agent.
- the concentration of the restoration agent used to reverse the anticoagulation will depend, in part, upon the concentration of the anticoagulation agent in the platelet rich plasma 100 and the stoichiometry of the chelating and coagulation reactions. However, the concentration of the restoration agent used to reverse the anticoagulation must be sufficient to achieve clot formation.
- a clot 110 Upon restoration of the platelet rich plasma 100 as shown in FIG. 2 b , a clot 110 will naturally form.
- the resulting clot 110 is then triturated by high-speed centrifugation, or squeezed through a mesh, thus releasing a serum 120 that comprises thrombin.
- the serum 120 is then mixed with the second portion of platelet rich plasma (PRP) 100 to form the bioadhesive sealant composition 130 of the present invention in less than two minutes and in quantities sufficient for clinical use.
- PRP platelet rich plasma
- serum 120 is mixed with the platelet poor plasma 200 of phase-two thereby forming the autologous bioadhesive sealant composition 140 of the present invention in less than two minutes.
- a third embodiment of the present invention, route 105 contemplates collecting the original quantity of platelet rich plasma (PRP) 100 derived from the anticoagulated whole blood 90 in a container, having a wettable surface, such as glass.
- PRP platelet rich plasma
- the platelet rich plasma 100 is then recalcified and the bioadhesive sealant composition 150 forms.
- the desired bioadhesive sealant composition 150 will require approximately two to eight minutes to form as opposed to less than a two minute formation as was described in the preferred embodiment.
- the platelet poor plasma 200 is divided into two portions, as discussed previously in the preferred embodiment.
- the first portion, used in phase-one, which is approximately 1/4 to 1 ⁇ 2 the original volume is stored in a container having a wettable surface, then the restoration agent, preferably calcium chloride, is added directly to the platelet poor plasma 200 .
- the restoration agent preferably calcium chloride
- Surface activation of the restored platelet poor plasma 200 occurs as result of the container's surface and a clot forms.
- the resulting clot is triturated, as described previously, and the serum 220 is collected. Serum 220 is then mixed with the platelet rich plasma 100 of phase-two thereby forming the autologous bioadhesive sealant composition 230 .
- serum 220 is mixed with the platelet poor plasma 200 of phase-two thereby forming the bioadhesive sealant composition 240 in less than two minutes.
- the sixth embodiment follows route 205 , shown in FIG. 2 c wherein the original quantity of platelet poor plasma 200 , derived from the anticoagulated whole blood minus platelet rich plasma 190 , is collected in a container having a wettable surface, such as glass. The platelet poor plasma 200 is then recalcified and the bioadhesive sealant composition 250 forms.
- a seventh embodiment contemplates mixing human recombinant thromboplastin directly with the platelet rich plasma to form a bioadhesive sealant composition (not shown).
- human recombinant thromboplastin is utilized to generate thrombin in a small aliquot of plasma and then the resulting thrombin is combined with the platelet rich plasma to form a bioadhesive sealant.
- Thromboplastin may be later removed by centrifugation.
- the tensile strength of the bioadhesive sealant compositions of the present invention can be affected by the addition of calcium ions. Consequently, if a stronger bioadhesive sealant composition is desired using the methods discussed above and disclosed in routes 101 and 201 , in FIGS. 2 b and 2 c , respectively, more calcium ions may be added at the time the serum is introduced into the platelet rich plasma 100 or the platelet poor plasma 200 . Alternatively, if the method of preparing the bioadhesive sealant compositions follows routes 105 and 205 , depicted in FIGS. 2 b and 2 c , respectively, then calcium ions may be introduced directly into the platelet rich plasma 100 or the platelet poor plasma 200 and the bioadhesive sealant compositions 150 and 250 , respectively, will form.
- the time period necessary for the formation of the bioadhesive sealant composition of the present invention is dependent on the quantity of serum added.
- a 1:4, 1:2 and 3:4 ratio of serum to platelet rich plasma or platelet poor plasma results in the formation of the bioadhesive gel composition in approximately 90, 55 and 30 seconds, respectively.
- thrombin is autocatalytic, it is important that the serum be used within five hours of preparation, preferably within two hours and ideally immediately. Alternatively, the serum can be chilled or frozen indefinitely.
- bioadhesive sealant compositions of this invention may be used for sealing a surgical wound by applying to the wound a suitable amount platelet rich plasma or platelet poor plasma once it has begun to gel. Moreover, due to the fact that the bioadhesive sealant compositions of the present invention have been prepared solely from blood components derived from the patient that is to receive the bioadhesive sealant there is a zero probability of introducing a new blood transmitted disease to the patient.
- the methods of the present invention may be further modified so that the formed bioadhesive sealant composition functions not only as a haemostatic agent, but also as an adjunct to wound healing and as a matrix for delivery of drugs and proteins with other biologic activities.
- fibrin glue has a great affinity to bind bone fragments, which is useful in bone reconstruction, as in plastic surgery or the repair of major bone breaks. Consequently, in keeping with the autologous nature of the bioadhesive sealant composition of the present invention, autologous bone from a patient can be ground or made into powder or the like, and mixed into the platelet rich plasma obtained in phase-two of the methods of the present invention. Serum comprising thrombin is then mixed in with the platelet rich plasma and bone fragments in an amount sufficient to allow the resulting gel to be applied to the desired locale where it congeals.
- the method of the present invention may be modified as follows. Prior to adding the serum comprising thrombin obtained in phase-one to the platelet rich plasma of phase-two, a wide variety of drugs or proteins with other biologic activities may be added to the platelet rich plasma of phase-two.
- agents to be added to the platelet rich plasma prior to the addition of the serum include, but are not limited to, analgesic compounds, antibacterial compounds, including bactericidal and bacteriostatic compounds, antibiotics (e.g., adriamycin, erythromycin, gentimycin, penicillin, tobramycin), antifungal compounds, anti-inflammatories, antiparasitic compounds, antiviral compounds, enzymes, enzyme inhibitors, glycoproteins, growth factors (e.g.
- lymphokines cytokines
- hormones steroids, glucocorticosteroids, immunomodulators, immunoglobulins, minerals, neuroleptics, proteins, peptides, lipoproteins, tumoricidal compounds, tumorstatic compounds, toxins and vitamins (e.g., Vitamin A, Vitamin E, Vitamin B, Vitamin C, Vitamin D, or derivatives thereof). It is also envisioned that selected fragments, portions, derivatives, or analogues of some or all of the above may be used.
- Some of the more successful techniques of evaluating blood clotting and coagulation are the plunger techniques illustrated by U.S. Pat. No. 4,599,219 to Cooper et al., U.S. Pat. No. 4,752,449 to Jackson et al., and U.S. Pat. No. 5,174,961 to Smith, all of which are assigned to the assignee of the present invention, and all of which are incorporated herein by reference.
- Automated apparatuses employing the plunger technique for measuring and detecting coagulation and coagulation-related activities generally comprise a plunger sensor cartridge or cartridges and a microprocessor controlled apparatus into which the cartridge is inserted.
- the apparatus acts upon the cartridge and the blood sample placed therein to induce and detect the coagulation-related event.
- the cartridge includes a plurality of test cells, each of which is defined by a tube-like member having an upper reaction chamber where a plunger assembly is located and where the analytical test is carried out, and a reagent chamber which contains a reagent or reagents.
- the reagents include an activation reagent to activate coagulation of the blood.
- a plug member seals the bottom of a reagent chamber.
- the contents of the reagent chamber are forced into the reaction chamber to be mixed with the sample of fluid, usually human blood or its components.
- An actuator which is a part of the apparatus, lifts the plunger assembly and lowers it, thereby reciprocating the plunger assembly through the pool of fluid in the reaction chamber.
- the plunger assembly descends by the force of gravity, resisted by a property of the fluid in the reaction chamber, such as its viscosity.
- the property of the sample changes in a predetermined manner as a result of the onset or occurrence of a coagulation-related activity, the descent rate of the plunger assembly therethrough is changed. Upon a sufficient change in the descent rate, the coagulation-related activity is detected and indicated by the apparatus.
- 10 cc's of whole blood is withdrawn from a patient, placed into a sterile glass tube, and allowed to clot naturally.
- the clot may be subsequently squeezed or centrifuged to release approximately 4-6 cc's of serum.
- Examples 1 and 2 may be simultaneously prepared for (a) an additional source of serum; and (b) to confirm successful coagulation.
Abstract
Description
- This patent application is a Continuation of U.S. patent application Ser. No. 10/173,839, filed Jun. 18, 2002, which is a Continuation of U.S. patent application Ser. No. 09/063,338, filed Apr. 20, 1998, now issued as U.S. Pat. No. 6,444,228, which is a Continuation-in-Part of U.S. patent application Ser. No. 08/640,278, filed Apr. 30, 1996, abandoned.
- 1. Field of the Invention
- The present invention relates to autologous bioadhesive sealant compositions, and more particularly to a convenient and practical two-phase method for preparing a bioadhesive sealant specifically from blood components derived from the patient who is to receive the bioadhesive sealant.
- 2. Description of the State of the Art:
- When the lining of a blood vessel is damaged, a complex series of events takes place which is designed to prevent blood loss and, ultimately, to restore the integrity of the vessel. Although short-lived vasoconstriction and physical factors such as the pressure of extruded blood on the vessel wall may play some part in haemostasis, the main factors in the haemostatic mechanism are platelets and the blood coagulation system.
- Blood coagulation is the result of the complex interaction of a number of protein clotting factors through a cascade (
FIG. 1 ). In general, damage to the vascular endothelium exposes subendothelial structures, which attract platelets and induce them to aggregate reversibly. The protein thrombin, formed during activation of the coagulation pathway generates insoluble cross-linked fibrils of the protein fibrin and causes the platelets to aggregate irreversibly. The resulting platelet-fibrin clot is an effective barrier against loss of blood from the vascular system and also serves as a scaffold for subsequent repair of the lining of the blood vessel. - Bioadhesive sealants and fibrin glues represent a relatively new technological advance that duplicates the biological process of the final stage of blood coagulation. Clinical reports document the utility of fibrin glue in a variety of surgical fields, such as, cardiovascular, thoracic, transplantation, head and neck, oral, gastrointestinal, orthopedic, neurosurgical, and plastic surgery. At the time of surgery, the two primary components comprising the fibrin glue, fibrinogen and thrombin, are mixed together to form a clot. The clot adheres to the necessary tissues, bone, or nerve within seconds, but is then slowly reabsorbed by the body in approximately 10 days by fibrinolysis. Important features of fibrin glue is its ability to: (1) achieve haemostasis at vascular anastomoses particularly in areas which are difficult to approach with sutures or where suture placement presents excessive risk; (2) control bleeding from needle holes or arterial tears which cannot be controlled by suturing alone; and (3) obtain haemostasis in heparinized patients or those with coagulopathy. See, Borst, H. G., et al., J. Thorac. Cardiovasc. Surg., 84: 548-553 (1982); Walterbusch, G. J, et al., Thorac Cardiovasc. Surg., 30: 234-235 (1982); and Wolner, F. J, et al., Thorac. Cardiovasc. Surg., 30: 236-237 (1982).
- Despite the effectiveness and successful use of fibrin glue by medical practitioners in Europe, neither fibrin glue nor its essential components fibrinogen and thrombin are widely used in the United States. In large part, this stems from the 1978 U.S. Food and Drug Administration ban on the sale of commercially prepared fibrinogen concentrate made from pooled donors because of the risk of transmission of viral infection, in particular the hepatitis-causing viruses such as HBV and HCV (also known as non A, non B hepatitis virus). In addition, the more recent appearance of other lipid-enveloped viruses such as HIV, associated with AIDS, cytomegalovirus (CMV), as well as Epstein-Barr virus, and the herpes simplex viruses in fibrinogen preparations make it unlikely that there will be a change in this policy in the foreseeable future. For similar reasons, human thrombin is also not currently authorized for human use in the United States. Bovine thrombin, which is licensed for human use in the United States is obtained from bovine sources which do not appear to carry significant risks for HIV and hepatitis, although other bovine pathogens, such as bovine spongiform, encephalitis, may be present.
- There have been a variety of methods developed for preparing fibrin glue. For example, Rose, et al. discloses a method of preparing a cryoprecipitated suspension containing fibrinogen and Factor XIII useful as a precursor in the preparation of a fibrin glue which involves (a) freezing fresh plasma from a single donor such as a human or other animal, e.g. a cow, sheep or pig, which has been screened for blood transmitted diseases, e.g. one or more of syphilis, hepatitis or acquired immune deficiency syndrome at about −80° C. for at least about 6 hours, preferably for at least about 12 hours; (b) raising the temperature of the frozen plasma, e.g. to between about 0° C. and room temperature, so as to form a supernatant and a cryoprecipitated suspension containing fibrinogen and Factor XIII; and (c) recovering the cryoprecipitated suspension. The fibrin glue is then prepared by applying a defined volume of the cyroprecipitate suspension described above and applying a composition containing a sufficient amount of thrombin, e.g. human, bovine, ovine or porcine thrombin, to the site so as to cause the fibrinogen in the suspension to be converted to the fibrin glue which then solidifies in the form of a gel. See U.S. Pat. No. 4,627,879.
- A second technique for preparing fibrin glue is disclosed by Marx in U.S. Pat. No. 5,607,694. Essentially a cryoprecipitate as discussed previously serves as the source of the fibrinogen component and then Marx adds thrombin and liposomes. A third method discussed by Berruyer, M. et al., entitled “Immunization by Bovine Thrombin Used with Fibrin Glue During Cardiovascular Operations,” (J. Thorac. Cardiovasc. Surg., 105(5): 892-897 (1992)) discloses a fibrin glue prepared by mixing bovine thrombin not only with human coagulant proteins, such as fibrinogen, fibronectin, Factor XIII, and plasminogen, but also with bovine aprotinin and calcium chloride.
- The above patents by Rose, et al., and Marx, and the technical paper by Berruyer, et al. each disclose methods for preparing fibrin sealants; however, each of these methods suffer disadvantages associated with the use of bovine thrombin as the activating agent. A serious and life threatening consequence associated with the use of fibrin glues comprising bovine thrombin is that patients have been reported to have a bleeding diathesis after receiving topical bovine thrombin. This complication occurs when patients develop antibodies to the bovine factor V in the relatively impure bovine thrombin preparations. These antibodies cross-react with human factor V, thereby causing a factor V deficiency that can be sufficiently severe to induce bleeding and even death. See, Rapaport, S. I., et al., Am. J. Clin. Pathol., 97: 84-91 (1992); Berruyer, M., et al., J Thorac. Cardiovasc. Surg., 105: 892-897 (1993); Zehnder, J., et al., Blood, 76(10): 2011-2016 (1990); Muntean, W., et al., Acta Paediatr., 83: 84-7 (1994); Christine, R. J., et al., Surgery, 127: 708-710 (1997).
- A further disadvantage associated with the methods disclosed by Marx and Rose, et al. is that the cryoprecipitate preparations require a large time and monetary commitment to prepare. Furthermore, great care must be taken to assure the absence of any viral contaminants.
- A final disadvantage associated with the methods previously disclosed is that while human thrombin is contemplated for use as an activator, human thrombin is not available for clinical use and there is no evidence that patients will not have an antigenic response to human thrombin. By analogy, recombinant human factor VIII has been shown to produce antigenic responses in hemophiliacs. See, Biasi, R. de., Thrombosis and Haemostasis, 71(5): 544-547 (1994). Consequently, until more clinical studies are performed on the effect of human recombinant thrombin one cannot merely assume that the use of recombinant human thrombin would obviate the antigenic problems associated with bovine thrombin. A second difficulty with thrombin is that it is autocatalytic, that is, it tends to self-destruct making handling and prolonged storage a problem.
- There is still a need, therefore, for a convenient and practical method for preparing a bioadhesive sealant composition wherein the resulting bioadhesive sealant poses a zero risk of disease transmission and a zero risk of causing an adverse physiological reaction.
- Accordingly, this invention provides a method for preparing a completely autologous bioadhesive sealant composition.
- This invention further provides an autologous bioadhesive sealant composition wherein the risks associated with the use of bovine and recombinant human thrombin are eliminated.
- This invention further provides an autologous bioadhesive sealant composition or fibrin glue prepared by a two-phase method, wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied.
- Additional advantages and novel features of this invention shall be set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the following specification or may be learned by the practice of the invention. The objects and advantages of the invention may be realized and attained by means of the instrumentalities, combinations, compositions, and methods particularly pointed out in the appended claims.
- To achieve the foregoing and in accordance with the purposes of the present invention, as embodied and broadly described therein, the method of this invention comprises the formation of an autologous bioadhesive sealant comprising the steps of forming a platelet rich plasma or platelet poor plasma containing an anticoagulant. The platelet rich plasma or platelet poor plasma is then divided into two portions and the first portion is restored so that it can coagulate, thus forming a clot. The clot is triturated and the resulting serum is collected. The bioadhesive sealant composition is then prepared by combining a defined volume of the second portion of platelet rich plasma or platelet poor plasma with a sufficient volume of serum causing the fibrinogen in the second portion of platelet rich plasma or platelet poor plasma to be converted to fibrin, which then solidifies in the form of a gel.
- The accompanying drawings, which are incorporated herein and form a part of the specification illustrate preferred embodiments of the present invention, and together with the description, serve to explain the principles of the invention.
- In The Drawings:
-
FIG. 1 is a diagrammatic representation of the blood coagulation cascade. -
FIG. 2 a is a flow diagram representing the initial portion of the method of the present invention used to obtain platelet rich plasma and platelet poor plasma. -
FIG. 2 b is a flow diagram representing the final portion of the method for preparing the bioadhesive sealant composition of the present invention using platelet rich plasma as a starting material. -
FIG. 2 c is a flow diagram representing the final portion of the method for preparing the bioadhesive sealant composition of the present invention using platelet poor plasma as a starting material. -
FIG. 3 is a graphic representation of the effect that the serum-to-plasma ratio has on clotting times. -
FIG. 4 a is a graphic representation of the relationship between clotting time and actual gel time using blood drawn from a donor. -
FIG. 4 b is a graphic representation of the relationship between clotting time and actual gel time using blood drawn from a donor. -
FIG. 5 a graphically represents the effect of calcium addition on clotting times and gel times using blood drawn from a donor. -
FIG. 5 b graphically represents the effect of calcium addition on clotting times and gel times using blood drawn from a donor. -
FIG. 6 graphically represents the effect of calcium addition on the clotting times of platelet rich plasma and platelet poor plasma. - In general, the present invention relates to a two-phase method, shown in
FIGS. 2 a, 2 b and 2 c, for forming an autologous bioadhesive sealant composition or fibrin glue wherein all of the blood components for the bioadhesive sealant are derived from a patient to whom the bioadhesive sealant will be applied. First, a platelet rich plasma and a platelet poor plasma are formed by centrifuging a quantity of anticoagulated whole blood that was previously drawn from the patient. The platelet rich plasma and platelet poor plasma are then divided into two portions. To the first portion, which is used in phase-one, a compound that reverses the effect of the anticoagulant is added, and a clot is allowed to form. The clot is then triturated and the resulting serum, containing autologous thrombin, is collected. The serum obtained from phase-one is then mixed with the second portion of the platelet rich plasma or platelet poor plasma, used in phase-two, to form the bioadhesive sealant of the present invention. - The method of the present invention for preparing an autologous bioadhesive composition, discussed in further detail below, is represented in the flow diagram depicted in
FIGS. 2 a, 2 b and 2 c. The method of the present invention begins by forming anticoagulatedwhole blood 90, which is achieved by collecting a patient'swhole blood 80 in a medium containing an anticoagulation agent, such as sodium citrate (citrate) or heparin. The act of drawing blood initiates clotting reactions, and unless something is done to stop the process, a clot will form. The formation of a clot is a multi-step process and several of these steps require the presence of calcium ions. By removing the calcium ions present in whole blood, as is the effect when the blood is collected in citrate, the blood can be prevented from clotting. To reinitiate the clot-forming process, calcium is added back into the whole blood (recalcification). A calcium chelating agent is a chemical that reacts with the calcium, present in blood, in such a fashion that the calcium can no longer function in blood coagulation. The most common chelating agent is a salt of citric acid (citrate), since it has the fewest side effects on the components of the clotting system. By collecting blood into a medium containing a calcium chelating agent such as citrate, sample collection and further preparations of the citrated sample can be performed over a time period of up to several hours. - Preferably, the
whole blood 80 is collected and mixed with a 3.8% solution of sodium citrate (referred to herein as “citrate collection medium”) specifically in a 9:1 ratio of blood to citrate collection medium. A 3.8% solution of sodium citrate is prepared by adding 3.8 grams of sodium citrate per 100 ml of water. While a 3.8% sodium citrate collection medium is that which is frequently used to collect and preserve blood, the person skilled in this art will recognize that the ratio of sodium citrate to whole blood could be in the range of about 10.9-12.9% mMAL, final concentration. - The anticoagulated
whole blood 90 is next centrifuged at a rate of approximately 20-50 r.c.f.'s (relative centrifugal force) for 10-40 minutes, and preferably in a refrigerated centrifuge at 25 r.c.f.'s for 20 minutes, resulting in the formation of two liquid phases. The top phase is a platelet rich plasma (PRP) 100, and the bottom phase is anticoagulated whole blood minus the plateletrich plasma 190. The platelet rich plasma (PRP) 100 is then gently drawn off and saved in a container. - The remaining anticoagulated whole blood minus the platelet
rich plasma phase 190 is further centrifuged at a rate of approximately 3000-4500 r.c.f.'s for 15-30 minutes, and preferably in a refrigerated centrifuge at 3850 r.c.f.'s for 20 minutes. This higher rate of centrifugation results in the red blood cells, white blood cells and platelets being spun out of the anticoagulated whole blood minus the plateletrich plasma phase 190 thereby forming a pellet (not shown) comprising cellular components which is to be discarded. The resulting platelet poor plasma (PPP) 200 is then decanted from the pellet and saved in a container. - The containers (not shown), which store the platelet
rich plasma 100 and plateletpoor plasma 200, may have either wettable surfaces (such as, silica, diatomaceous earth, kaolin, etc.) or non-wettable surfaces (such as plastic, siliconized glass, etc.). Since surfaces play a role in activating blood coagulation, the surface of the container chosen to store either the plateletrich plasma 100 or the plateletpoor plasma 200 is dependent on whether clot formation is desired quickly or slowly. Chemical activators, such as kaolin, can also be used to speed up the clotting time; however, their subsequent removal would also be necessary. In the preferred embodiment, a glass tube is the preferred container used to collect the plateletrich plasma 100 and the plateletpoor plasma 200. - In the preferred embodiment, according to
route 101, the plateletrich plasma 100 is divided into two portions. The first portion is approximately 1/4 to ½ of the total volume of plateletrich plasma 100 and is utilized in phase-one to prepare the thrombin, while the second portion of plateletrich plasma 100 is utilized in phase-two. Once the plateletrich plasma 100 and the plateletpoor plasma 200 are obtained, the preferred methods to obtain the bioadhesive sealant compositions in an expedited manner, that is, in less than two minutes, are detailed diagrammatically inroutes FIGS. 2 b and 2 c, respectively and discussed in detail below. If, however, a longer clotting time, that is, in a range of two to eight minutes, is desirous, the method to obtain the bioadhesive sealant composition of the present invention can proceed along theroutes FIGS. 2 b and 2 c, respectively and discussed in detail below. - Phase one according to the preferred embodiment begins by restoring the clot-forming process. To accomplish this, an agent (restoration agent) capable of reversing the effects of the anticoagulation agent is added back into the first portion of the platelet
rich plasma 100. In the presently preferred embodiment of the invention, the reversal of the anticoagulant is accomplished using calcium chloride. However, any substance that is known or found to be functionally equivalent to calcium chloride, such as, calcium gluconate, in restoring the coagulation activity of citrated blood may be used in the practice of the present invention. Thus, although calcium chloride is the presently preferred calcium salt for use in the invention, any calcium salt which functions in a similar manner to calcium chloride may be used in the invention. Similarly, although many blood coagulation reactions are currently believed to require calcium ions as cofactors, any substance that is known or subsequently found to be functionally equivalent to calcium in facilitating these coagulation reactions may be used, either individually or in combination with calcium, in the practice of the present invention. If the anticoagulation agent used was heparin, then heparinase would be used to reverse the effect of the anticoagulation agent. The concentration of the restoration agent used to reverse the anticoagulation will depend, in part, upon the concentration of the anticoagulation agent in the plateletrich plasma 100 and the stoichiometry of the chelating and coagulation reactions. However, the concentration of the restoration agent used to reverse the anticoagulation must be sufficient to achieve clot formation. - Upon restoration of the platelet
rich plasma 100 as shown inFIG. 2 b, aclot 110 will naturally form. The resultingclot 110 is then triturated by high-speed centrifugation, or squeezed through a mesh, thus releasing aserum 120 that comprises thrombin. In the preferred embodiment, theserum 120 is then mixed with the second portion of platelet rich plasma (PRP) 100 to form thebioadhesive sealant composition 130 of the present invention in less than two minutes and in quantities sufficient for clinical use. - In an alternative embodiment,
serum 120 is mixed with the plateletpoor plasma 200 of phase-two thereby forming the autologousbioadhesive sealant composition 140 of the present invention in less than two minutes. - A third embodiment of the present invention,
route 105, shown inFIG. 2 b, contemplates collecting the original quantity of platelet rich plasma (PRP) 100 derived from the anticoagulatedwhole blood 90 in a container, having a wettable surface, such as glass. The plateletrich plasma 100 is then recalcified and thebioadhesive sealant composition 150 forms. The desiredbioadhesive sealant composition 150 will require approximately two to eight minutes to form as opposed to less than a two minute formation as was described in the preferred embodiment. - In the fourth embodiment depicted diagrammatically by
route 201 inFIG. 2 c, the plateletpoor plasma 200, rather then the plateletrich plasma 100, is divided into two portions, as discussed previously in the preferred embodiment. The first portion, used in phase-one, which is approximately 1/4 to ½ the original volume is stored in a container having a wettable surface, then the restoration agent, preferably calcium chloride, is added directly to the plateletpoor plasma 200. Surface activation of the restored plateletpoor plasma 200 occurs as result of the container's surface and a clot forms. The resulting clot is triturated, as described previously, and theserum 220 is collected.Serum 220 is then mixed with the plateletrich plasma 100 of phase-two thereby forming the autologousbioadhesive sealant composition 230. - In the fifth embodiment,
serum 220 is mixed with the plateletpoor plasma 200 of phase-two thereby forming thebioadhesive sealant composition 240 in less than two minutes. - The sixth embodiment follows
route 205, shown inFIG. 2 c wherein the original quantity of plateletpoor plasma 200, derived from the anticoagulated whole blood minus plateletrich plasma 190, is collected in a container having a wettable surface, such as glass. The plateletpoor plasma 200 is then recalcified and thebioadhesive sealant composition 250 forms. - A seventh embodiment contemplates mixing human recombinant thromboplastin directly with the platelet rich plasma to form a bioadhesive sealant composition (not shown). Alternatively, human recombinant thromboplastin is utilized to generate thrombin in a small aliquot of plasma and then the resulting thrombin is combined with the platelet rich plasma to form a bioadhesive sealant. Thromboplastin may be later removed by centrifugation.
- The tensile strength of the bioadhesive sealant compositions of the present invention can be affected by the addition of calcium ions. Consequently, if a stronger bioadhesive sealant composition is desired using the methods discussed above and disclosed in
routes FIGS. 2 b and 2 c, respectively, more calcium ions may be added at the time the serum is introduced into the plateletrich plasma 100 or the plateletpoor plasma 200. Alternatively, if the method of preparing the bioadhesive sealant compositions followsroutes FIGS. 2 b and 2 c, respectively, then calcium ions may be introduced directly into the plateletrich plasma 100 or the plateletpoor plasma 200 and thebioadhesive sealant compositions - As discussed in further detail below, the time period necessary for the formation of the bioadhesive sealant composition of the present invention is dependent on the quantity of serum added. A 1:4, 1:2 and 3:4 ratio of serum to platelet rich plasma or platelet poor plasma results in the formation of the bioadhesive gel composition in approximately 90, 55 and 30 seconds, respectively. Furthermore, due to the fact that thrombin is autocatalytic, it is important that the serum be used within five hours of preparation, preferably within two hours and ideally immediately. Alternatively, the serum can be chilled or frozen indefinitely.
- The bioadhesive sealant compositions of this invention may be used for sealing a surgical wound by applying to the wound a suitable amount platelet rich plasma or platelet poor plasma once it has begun to gel. Moreover, due to the fact that the bioadhesive sealant compositions of the present invention have been prepared solely from blood components derived from the patient that is to receive the bioadhesive sealant there is a zero probability of introducing a new blood transmitted disease to the patient.
- The methods of the present invention may be further modified so that the formed bioadhesive sealant composition functions not only as a haemostatic agent, but also as an adjunct to wound healing and as a matrix for delivery of drugs and proteins with other biologic activities. For example, it is well known that fibrin glue has a great affinity to bind bone fragments, which is useful in bone reconstruction, as in plastic surgery or the repair of major bone breaks. Consequently, in keeping with the autologous nature of the bioadhesive sealant composition of the present invention, autologous bone from a patient can be ground or made into powder or the like, and mixed into the platelet rich plasma obtained in phase-two of the methods of the present invention. Serum comprising thrombin is then mixed in with the platelet rich plasma and bone fragments in an amount sufficient to allow the resulting gel to be applied to the desired locale where it congeals.
- In instances where the desired bioadhesive sealant composition of the present invention is to further function as a delivery device of drugs and proteins with other biologic activities the method of the present invention may be modified as follows. Prior to adding the serum comprising thrombin obtained in phase-one to the platelet rich plasma of phase-two, a wide variety of drugs or proteins with other biologic activities may be added to the platelet rich plasma of phase-two. Examples of the agents to be added to the platelet rich plasma prior to the addition of the serum include, but are not limited to, analgesic compounds, antibacterial compounds, including bactericidal and bacteriostatic compounds, antibiotics (e.g., adriamycin, erythromycin, gentimycin, penicillin, tobramycin), antifungal compounds, anti-inflammatories, antiparasitic compounds, antiviral compounds, enzymes, enzyme inhibitors, glycoproteins, growth factors (e.g. lymphokines, cytokines), hormones, steroids, glucocorticosteroids, immunomodulators, immunoglobulins, minerals, neuroleptics, proteins, peptides, lipoproteins, tumoricidal compounds, tumorstatic compounds, toxins and vitamins (e.g., Vitamin A, Vitamin E, Vitamin B, Vitamin C, Vitamin D, or derivatives thereof). It is also envisioned that selected fragments, portions, derivatives, or analogues of some or all of the above may be used.
- A number of different medical apparatuses and testing methods exist for measuring and determining coagulation and coagulation-related activities of blood. These apparatuses and methods can be used to assist in determining the optimal formulation of activator, that is, thrombin, calcium and plasma necessary to form the bioadhesive sealant composition of the present invention. Some of the more successful techniques of evaluating blood clotting and coagulation are the plunger techniques illustrated by U.S. Pat. No. 4,599,219 to Cooper et al., U.S. Pat. No. 4,752,449 to Jackson et al., and U.S. Pat. No. 5,174,961 to Smith, all of which are assigned to the assignee of the present invention, and all of which are incorporated herein by reference.
- Automated apparatuses employing the plunger technique for measuring and detecting coagulation and coagulation-related activities generally comprise a plunger sensor cartridge or cartridges and a microprocessor controlled apparatus into which the cartridge is inserted. The apparatus acts upon the cartridge and the blood sample placed therein to induce and detect the coagulation-related event. The cartridge includes a plurality of test cells, each of which is defined by a tube-like member having an upper reaction chamber where a plunger assembly is located and where the analytical test is carried out, and a reagent chamber which contains a reagent or reagents. For an activated clotting time (ACT) test, for example, the reagents include an activation reagent to activate coagulation of the blood. A plug member seals the bottom of a reagent chamber. When the test commences, the contents of the reagent chamber are forced into the reaction chamber to be mixed with the sample of fluid, usually human blood or its components. An actuator, which is a part of the apparatus, lifts the plunger assembly and lowers it, thereby reciprocating the plunger assembly through the pool of fluid in the reaction chamber. The plunger assembly descends by the force of gravity, resisted by a property of the fluid in the reaction chamber, such as its viscosity. When the property of the sample changes in a predetermined manner as a result of the onset or occurrence of a coagulation-related activity, the descent rate of the plunger assembly therethrough is changed. Upon a sufficient change in the descent rate, the coagulation-related activity is detected and indicated by the apparatus.
- Using the methods discussed above, cartridges were assembled with serum obtained from either platelet rich plasma or platelet poor plasma, and CaC12 in the reagent chambers. Clotting time tests were performed by the automated process with either platelet rich plasma (PRP) or platelet poor plasma (PPP) dispersed into the reaction chambers of the cartridges. In the first experiment, the results of which are represented in
FIG. 3 , the amount of serum, the type of plasma from which the serum was derived, and the type of plasma the serum was mixed with were tested to determine the shortest clotting times. The ratios of serum to platelet rich plasma or platelet poor plasma that were studied included 1:4, 1:2, and 3:4. In the second set of experiments, the results of which are represented inFIGS. 4 a and 4 b, the relationship between actual gel time for the bioadhesive sealant composition of the present was compared to the clotting time in the cartridge, wherein there is a 0, 30, or 60-minute delay of adding the serum from its generation. The third set of experiments, the results of which are represented inFIGS. 5 a and 5 b, studied the effect of calcium addition on actual gel time versus clotting time in the cartridge. The final set of experiments, the results of which are represented inFIG. 6 , studied the effect of adding calcium on clotting times. - Although clotting times varied among donors, comparisons of clotting times for individual donors show significant effects of the serum to plasma ratio and the calcium concentration. For all donors, the shortest clotting times occurred for the 3:4 ratio, with clotting times that were 47% shorter than those for the 1:4 ratio. Although the difference in clotting times for the 3:4 ratio and the 1:2 ratio was not statistically significant, the clotting times were consistently shorter using the 3:4 ratio for all donors. These results demonstrate that clotting times may be shortened by increasing the serum to platelet rich plasma ratio. Similarly, clotting times were significantly affected by the amount of calcium added, with the shortest clotting times obtained when no calcium was added, suggesting that the serum contained levels, of calcium that were sufficient to recalcify the citrated platelet rich plasma. Preliminary results from the scale-up experiments suggest that experimental clotting times in the cartridges correlate with actual gel times.
- The invention is further illustrated by the following non-limited examples. All scientific and technical terms have the meanings as understood by one with ordinary skill in the art. The specific examples that follow illustrate the methods in which the bioadhesive sealant compositions of the present invention may be prepared in a clinical setting and are not to be construed as limiting the invention in sphere or scope. The methods may be adapted to variation in order to produce compositions embraced by this invention but not specifically disclosed. Further, variations of the methods to produce the same compositions in somewhat different fashion will be evident to one skilled in the art.
- The examples herein are meant to exemplify the various aspects of carrying out the invention and are not intended to limit the invention in any way.
- 10 cc's of platelet rich plasma is added to a sterile glass tube containing 0.33 cc's of 10% calcium chloride. A stopper is placed in the tube and the contents are gently mixed and the tube is set aside. Gelling of the contents will occur in two to eight minutes. The gel is passed to a dry sterile cup where it is squeezed out 4-6 cc's of the serum, produced therefrom, and 1 cc of air is drawn into a syringe containing 4 cc of platelet rich plasma along with 1 cc of the serum. The bioadhesive sealant composition will gel inside the syringe within approximately two minutes. The gel time may be decreased by increasing the amount of serum added to the platelet rich plasma.
- 10 cc's of whole blood is withdrawn from a patient, placed into a sterile glass tube, and allowed to clot naturally. The clot may be subsequently squeezed or centrifuged to release approximately 4-6 cc's of serum.
- An equivalent volume of 10% calcium chloride is then mixed with the serum. 1 cc of this calcified serum is then mixed with 7-8 cc's of platelet rich plasma and 2 cc's of air. The resulting bioadhesive sealant will gel in approximately 1-2 minutes.
- To a sterile glass syringe containing 0.33 cc's of 10% calcium chloride is added 10 cc's of platelet rich plasma. The mixture is allowed to rest for 2 to 8 minutes. Once the gel appears to be appropriately viscous, it may be applied to the wound site.
- The techniques demonstrated in Examples 1 and 2 may be simultaneously prepared for (a) an additional source of serum; and (b) to confirm successful coagulation.
- The foregoing description is considered as illustrative only of the principles of the invention. Furthermore, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and processes shown as described above. Accordingly, all suitable modifications and equivalents may be resorted to falling within the scope of the invention as defined by the claims that follow.
- The words “comprise,” “comprising,” “include,” “including,” and “includes,” when used in this specification and in the following claims, are intended to specify the presence of one or more stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.
Claims (53)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/049,010 US20050170006A1 (en) | 1996-04-30 | 2005-02-02 | Methods of applying a biological composition to an individual |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64027896A | 1996-04-30 | 1996-04-30 | |
US09/063,338 US6444228B1 (en) | 1996-04-30 | 1998-04-20 | Autologous fibrin sealant and method for making the same |
US10/173,839 US6830762B2 (en) | 1996-04-30 | 2002-06-18 | Autologous fibrin sealant and method for making the same |
US10/848,302 US20040213777A1 (en) | 1996-04-30 | 2004-05-18 | Methods of applying a biological composition to an individual |
US11/049,010 US20050170006A1 (en) | 1996-04-30 | 2005-02-02 | Methods of applying a biological composition to an individual |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/848,302 Continuation US20040213777A1 (en) | 1996-04-30 | 2004-05-18 | Methods of applying a biological composition to an individual |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050170006A1 true US20050170006A1 (en) | 2005-08-04 |
Family
ID=26743295
Family Applications (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/832,729 Expired - Lifetime US6942639B2 (en) | 1996-04-30 | 2001-04-09 | Autologous platelet gel delivery system |
US09/833,234 Expired - Lifetime US6596180B2 (en) | 1996-04-30 | 2001-04-09 | System and method for the production of autologous platelet gel |
US09/832,517 Expired - Lifetime US6719901B2 (en) | 1996-04-30 | 2001-04-09 | System for the production of an autologous thrombin |
US10/173,839 Expired - Lifetime US6830762B2 (en) | 1996-04-30 | 2002-06-18 | Autologous fibrin sealant and method for making the same |
US10/738,439 Expired - Lifetime US6899813B2 (en) | 1996-04-30 | 2003-12-17 | Method for the production of a blood component composition |
US10/848,302 Abandoned US20040213777A1 (en) | 1996-04-30 | 2004-05-18 | Methods of applying a biological composition to an individual |
US11/004,023 Expired - Lifetime US7811607B2 (en) | 1996-04-30 | 2004-12-03 | Autologous fibrin sealant and method for making the same |
US11/044,984 Expired - Lifetime US7838039B2 (en) | 1996-04-30 | 2005-01-27 | Autologous fibrin sealant and method for making same |
US11/049,010 Abandoned US20050170006A1 (en) | 1996-04-30 | 2005-02-02 | Methods of applying a biological composition to an individual |
US11/115,076 Expired - Lifetime US7413652B2 (en) | 1996-04-30 | 2005-04-26 | Method for the production of a blood component composition |
US11/120,305 Expired - Lifetime US7934603B2 (en) | 1996-04-30 | 2005-05-02 | Autologous platelet gel spray delivery system |
US11/159,482 Expired - Lifetime US8303993B2 (en) | 1996-04-30 | 2005-06-23 | Methods of applying a biological composition to an individual |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/832,729 Expired - Lifetime US6942639B2 (en) | 1996-04-30 | 2001-04-09 | Autologous platelet gel delivery system |
US09/833,234 Expired - Lifetime US6596180B2 (en) | 1996-04-30 | 2001-04-09 | System and method for the production of autologous platelet gel |
US09/832,517 Expired - Lifetime US6719901B2 (en) | 1996-04-30 | 2001-04-09 | System for the production of an autologous thrombin |
US10/173,839 Expired - Lifetime US6830762B2 (en) | 1996-04-30 | 2002-06-18 | Autologous fibrin sealant and method for making the same |
US10/738,439 Expired - Lifetime US6899813B2 (en) | 1996-04-30 | 2003-12-17 | Method for the production of a blood component composition |
US10/848,302 Abandoned US20040213777A1 (en) | 1996-04-30 | 2004-05-18 | Methods of applying a biological composition to an individual |
US11/004,023 Expired - Lifetime US7811607B2 (en) | 1996-04-30 | 2004-12-03 | Autologous fibrin sealant and method for making the same |
US11/044,984 Expired - Lifetime US7838039B2 (en) | 1996-04-30 | 2005-01-27 | Autologous fibrin sealant and method for making same |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/115,076 Expired - Lifetime US7413652B2 (en) | 1996-04-30 | 2005-04-26 | Method for the production of a blood component composition |
US11/120,305 Expired - Lifetime US7934603B2 (en) | 1996-04-30 | 2005-05-02 | Autologous platelet gel spray delivery system |
US11/159,482 Expired - Lifetime US8303993B2 (en) | 1996-04-30 | 2005-06-23 | Methods of applying a biological composition to an individual |
Country Status (2)
Country | Link |
---|---|
US (12) | US6942639B2 (en) |
WO (1) | WO2000062828A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040213777A1 (en) * | 1996-04-30 | 2004-10-28 | Baugh Robert F. | Methods of applying a biological composition to an individual |
US20070093748A1 (en) * | 2005-06-23 | 2007-04-26 | Medtronic Vascular, Inc. | Methods and systems for treating injured cardiac tissue |
US20070172472A1 (en) * | 2005-06-23 | 2007-07-26 | Asha Nayak | Methods and Systems for Treating Injured Cardiac Tissue |
US20080044852A1 (en) * | 2006-04-26 | 2008-02-21 | Tessy Kanayinkal | Compositions and methods of preparation thereof |
US20090026123A1 (en) * | 1996-04-30 | 2009-01-29 | Dolecek Victor D | System for the production of autologus platelet gel useful for the delivery of medicinal and genetic agents |
US8586324B2 (en) | 2011-08-15 | 2013-11-19 | Biomet Biologics, Llc | Method and apparatus to create autologous clotting serum |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120156278A1 (en) * | 1997-06-24 | 2012-06-21 | Cascade Medical Enterprises, Llc | Systems and methods for preparing autologous fibrin glue |
US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
US20080199513A1 (en) * | 1997-06-24 | 2008-08-21 | Cascade Medical Enterprises, Llc | Systems and methods for preparing autologous fibrin glue |
US6709413B1 (en) * | 1999-09-02 | 2004-03-23 | Riverview Hospital | Platelet gel manufacturer for use in a closed corporeal circuit |
US6524231B1 (en) | 1999-09-03 | 2003-02-25 | Baxter International Inc. | Blood separation chamber with constricted interior channel and recessed passage |
US20040010393A1 (en) * | 2002-03-25 | 2004-01-15 | Barney Jonathan A. | Method and system for valuing intangible assets |
US20080267923A2 (en) * | 1999-11-05 | 2008-10-30 | Donald Kleinsek | Hair undifferentiated cells |
US7799325B2 (en) * | 1999-11-05 | 2010-09-21 | Kleinsek Donald A | Removal of hypertrophic scars |
US20090074729A2 (en) * | 1999-11-05 | 2009-03-19 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including fibroblasts |
EP1263931A4 (en) * | 1999-11-05 | 2009-07-15 | Gerigene Medical Corp | Augmentation and repair of age-related soft tissue defects |
US20080286242A2 (en) * | 1999-11-05 | 2008-11-20 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including mesenchymal cells |
US20090130066A1 (en) * | 2000-11-06 | 2009-05-21 | Gerigene Medical Corporation | Augmentation and repair of sphincter defects with cells including muscle cells |
US7740623B2 (en) * | 2001-01-13 | 2010-06-22 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
ES2173812B1 (en) * | 2001-03-01 | 2003-12-16 | Ct Investig Energeticas Ciemat | ARTIFICIAL DERMIS AND METHOD OF OBTAINING. |
WO2002080991A2 (en) * | 2001-04-09 | 2002-10-17 | Medtronic, Inc. | System for the production of autologous platelet gel |
US6942880B1 (en) | 2001-04-09 | 2005-09-13 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
WO2002081007A2 (en) * | 2001-04-09 | 2002-10-17 | Medtronic, Inc. | Methods of isolating blood components using a centrifuge and uses thereof |
US7247162B1 (en) | 2002-01-14 | 2007-07-24 | Edwards Lifesciences Corporation | Direct access atherectomy devices |
US7211037B2 (en) | 2002-03-04 | 2007-05-01 | Therakos, Inc. | Apparatus for the continuous separation of biological fluids into components and method of using same |
US7479123B2 (en) | 2002-03-04 | 2009-01-20 | Therakos, Inc. | Method for collecting a desired blood component and performing a photopheresis treatment |
US7608258B2 (en) * | 2002-04-13 | 2009-10-27 | Allan Mishra | Method for treatment of tendinosis using platelet rich plasma |
US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
ES2221770B2 (en) * | 2002-04-19 | 2006-07-16 | Eduardo Anitua Aldecoa | METHOD OF PREPARATION OF A COMPOUND FOR THE REGENERATION OF FABRICS. |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
DE10392686T5 (en) | 2002-05-24 | 2005-07-07 | Biomet Mfg. Corp., Warsaw | Apparatus and method for separating and concentrating liquids containing multiple components |
US6936033B2 (en) * | 2002-06-14 | 2005-08-30 | Medtronic, Inc. | Multiple ratio fluid dispenser |
US6982038B2 (en) * | 2002-06-14 | 2006-01-03 | Medtronic, Inc. | Centrifuge system utilizing disposable components and automated processing of blood to collect platelet rich plasma |
US7297272B2 (en) | 2002-10-24 | 2007-11-20 | Fenwal, Inc. | Separation apparatus and method |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7618948B2 (en) * | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US8246602B2 (en) * | 2002-12-23 | 2012-08-21 | Medtronic, Inc. | Catheters with tracking elements and permeable membranes |
ATE411063T1 (en) * | 2002-12-23 | 2008-10-15 | Medtronic Inc | MULTIPLE INFUSION CATHETER AND ASSOCIATED METHODS |
US8043281B2 (en) * | 2002-12-23 | 2011-10-25 | Medtronic, Inc. | Catheters incorporating valves and permeable membranes |
KR100490904B1 (en) * | 2002-12-24 | 2005-05-24 | 한국전자통신연구원 | Voltage Controlled Oscillator using Photonic Bandgap Structure and Feedforward circuit |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
US7998188B2 (en) * | 2003-04-28 | 2011-08-16 | Kips Bay Medical, Inc. | Compliant blood vessel graft |
ATE531338T1 (en) * | 2003-04-28 | 2011-11-15 | Kips Bay Medical Inc | ELASTIC VENOUS IMPLANT |
US20050131520A1 (en) * | 2003-04-28 | 2005-06-16 | Zilla Peter P. | Compliant blood vessel graft |
WO2005004886A1 (en) * | 2003-07-09 | 2005-01-20 | Sdgi Holdings, Inc. | Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation |
ATE515245T1 (en) | 2003-12-11 | 2011-07-15 | Isto Technologies Inc | PARTICLE CARTILAGE SYSTEM |
US20050137579A1 (en) * | 2003-12-23 | 2005-06-23 | Medtronic, Inc. | Permeable membrane catheters, systems, and methods |
US7354515B2 (en) * | 2004-02-23 | 2008-04-08 | Millennium Medical Technologies, Inc. | Fluid concentrator |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
US7837708B2 (en) * | 2004-04-22 | 2010-11-23 | Arthrex, Inc. | Accelerated healing with intraoperative combination of suture and autogenous blood components |
US7597687B2 (en) * | 2004-10-29 | 2009-10-06 | Spinal Restoration, Inc. | Injection of fibrin sealant including an anesthetic in spinal applications |
US8206448B2 (en) | 2004-10-29 | 2012-06-26 | Spinal Restoration, Inc. | Injection of fibrin sealant using reconstituted components in spinal applications |
DE102004036840B4 (en) * | 2004-07-29 | 2012-04-19 | Orthogen Ag | Method and means for obtaining platelet rich plasma |
US7462268B2 (en) | 2004-08-20 | 2008-12-09 | Allan Mishra | Particle/cell separation device and compositions |
US7718167B2 (en) * | 2004-09-13 | 2010-05-18 | Hynes Richard A | Method for treating wounds exposing the dura using PPP and PRP |
ES2264353B1 (en) * | 2004-10-26 | 2007-11-01 | Instituto Oftalmologico De Alicante,S.L. | BICOMPONENT BIOADHESIVE FOR BIOMEDICAL USE. |
US20060095121A1 (en) * | 2004-10-28 | 2006-05-04 | Medtronic Vascular, Inc. | Autologous platelet gel on a stent graft |
US20110213464A1 (en) * | 2004-10-29 | 2011-09-01 | Whitlock Steven I | Injection of fibrin sealant in the absence of corticosteroids in spinal applications |
ES2426172T3 (en) * | 2005-02-07 | 2013-10-21 | Hanuman Llc | Plasma concentrator device |
US7766900B2 (en) | 2005-02-21 | 2010-08-03 | Biomet Manufacturing Corp. | Method and apparatus for application of a fluid |
WO2006102488A1 (en) * | 2005-03-22 | 2006-09-28 | Cascade Medical Enterprises, Llc | Systems and methods of producing membranes |
WO2006106763A1 (en) * | 2005-03-30 | 2006-10-12 | Kaneka Corporation | Method of removing lymphocyte growth inhibitor |
US20060253068A1 (en) * | 2005-04-20 | 2006-11-09 | Van Bilsen Paul | Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart |
WO2009031990A1 (en) * | 2005-04-20 | 2009-03-12 | Millennium Medical Technologies, Inc. | Fluid concentrator |
US7635343B2 (en) * | 2005-04-21 | 2009-12-22 | Arteriocyte Medical Systems, Inc. | Fluid dispenser |
US7694828B2 (en) | 2005-04-27 | 2010-04-13 | Biomet Manufacturing Corp. | Method and apparatus for producing autologous clotting components |
WO2006121960A2 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
US20070042016A1 (en) * | 2005-06-23 | 2007-02-22 | Medtronic Vascular, Inc. | Methods and Systems for Treating Injured Cardiac Tissue |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
JP2009500352A (en) * | 2005-06-30 | 2009-01-08 | サイトメディックス インコーポレイテッド | Method of treating wounds with concentrated platelet wound healing agents |
EP1916964A4 (en) | 2005-08-26 | 2015-11-04 | Zimmer Inc | Implants and methods for repair, replacement and treatment of joint disease |
US7716226B2 (en) * | 2005-09-27 | 2010-05-11 | Patentratings, Llc | Method and system for probabilistically quantifying and visualizing relevance between two or more citationally or contextually related data objects |
US20070086958A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Formation of medically useful gels comprising microporous particles and methods of use |
US20070087061A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Method and composition for creating and/or activating a platelet-rich gel by contact with a porous particulate material, for use in wound care, tissue adhesion, or as a matrix for delivery of therapeutic components |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
ITRM20060289A1 (en) * | 2006-05-31 | 2007-12-01 | Ranieri Cancedda | BIO MEMBRANE ENGINEERED OSTEO ANGIOGENICA AND ITS USES FOR THE REGENERATION OF BONE FABRIC |
KR100855621B1 (en) | 2006-06-26 | 2008-09-01 | 연세대학교 산학협력단 | Apparatus and method manufacturing autologous thrombin and fibrinogen simultaneously |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
US20080089867A1 (en) * | 2006-10-13 | 2008-04-17 | Brian Fernandes | Method of increasing retention, survival and proliferation of transplanted cells in vivo |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US7988668B2 (en) * | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US7819842B2 (en) | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US8057426B2 (en) * | 2007-01-03 | 2011-11-15 | Medtronic Vascular, Inc. | Devices and methods for injection of multiple-component therapies |
US20080171906A1 (en) * | 2007-01-16 | 2008-07-17 | Everaerts Frank J L | Tissue performance via hydrolysis and cross-linking |
CA2684040C (en) | 2007-04-12 | 2016-12-06 | Isto Technologies, Inc. | Method of forming an implant using a mold that mimics the shape of the tissue defect site and implant formed therefrom |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
EP2146794B1 (en) | 2007-04-12 | 2016-10-19 | Biomet Biologics, LLC | Buoy suspension fractionation system |
WO2008148071A2 (en) * | 2007-05-24 | 2008-12-04 | Nidus2, Llc | Injectable dermis |
CN101801431B (en) * | 2007-06-22 | 2014-11-19 | 循环生物制品有限责任公司 | Fluid concentrator, autologous concentrated body fluids, and uses thereof |
KR100925603B1 (en) * | 2007-09-28 | 2009-11-06 | 삼성전기주식회사 | Multilayer capacitor |
US8000918B2 (en) * | 2007-10-23 | 2011-08-16 | Edwards Lifesciences Corporation | Monitoring and compensating for temperature-related error in an electrochemical sensor |
WO2009059203A1 (en) * | 2007-11-02 | 2009-05-07 | Edwards Lifesciences Corporation | Analyte monitoring system having back-up power source for use in either transport of the system or primary power loss |
US20090188811A1 (en) | 2007-11-28 | 2009-07-30 | Edwards Lifesciences Corporation | Preparation and maintenance of sensors |
EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
US8685258B2 (en) | 2008-02-27 | 2014-04-01 | Fenwal, Inc. | Systems and methods for conveying multiple blood components to a recipient |
US8075468B2 (en) | 2008-02-27 | 2011-12-13 | Fenwal, Inc. | Systems and methods for mid-processing calculation of blood composition |
US8337711B2 (en) | 2008-02-29 | 2012-12-25 | Biomet Biologics, Llc | System and process for separating a material |
US8182769B2 (en) | 2008-04-04 | 2012-05-22 | Biomet Biologics, Llc | Clean transportation system |
US8518272B2 (en) | 2008-04-04 | 2013-08-27 | Biomet Biologics, Llc | Sterile blood separating system |
WO2010002636A1 (en) * | 2008-07-02 | 2010-01-07 | Discoverx Corporation | Assays for nuclear hormone receptor binding |
EP2329255A4 (en) | 2008-08-27 | 2014-04-09 | Edwards Lifesciences Corp | Analyte sensor |
US20100112081A1 (en) * | 2008-10-07 | 2010-05-06 | Bioparadox, Llc | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
WO2010042762A1 (en) | 2008-10-09 | 2010-04-15 | Bioparadox, Llc | Platelet rich plasma formulations for cardiac treatments |
US20100112696A1 (en) * | 2008-11-03 | 2010-05-06 | Baxter International Inc. | Apparatus And Methods For Processing Tissue To Release Cells |
US8309343B2 (en) | 2008-12-01 | 2012-11-13 | Baxter International Inc. | Apparatus and method for processing biological material |
JP5866203B2 (en) | 2009-02-05 | 2016-02-17 | ピエール フィリッパール, | Methods and means for tissue production and the resulting tissue |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US20100233282A1 (en) * | 2009-03-13 | 2010-09-16 | Allan Mishra | Device and methods for delivery of bioactive materials to the right side of the heart |
KR101225664B1 (en) | 2009-03-16 | 2013-01-23 | 주식회사 메디사랑 | Fibrin forming method using platelet rich plasma clot |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
KR20100116106A (en) * | 2009-04-21 | 2010-10-29 | 에스타 테크날러지스 리미티드 | Assembly, kit and method for preparing platelet-rich plasma (prp) |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
AU2011238579A1 (en) * | 2010-03-30 | 2012-10-18 | Battelle Memorial Institute | Buffy coat separator float systems and methods |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
WO2012012507A2 (en) * | 2010-07-23 | 2012-01-26 | Biomatrx Llc | Methods, inserts, and systems useful for endodontic treatment |
US9555171B2 (en) | 2010-09-30 | 2017-01-31 | Depuy Mitek, Llc | Methods and devices for collecting separate components of whole blood |
US8556794B2 (en) | 2010-11-19 | 2013-10-15 | Kensey Nash Corporation | Centrifuge |
US8317672B2 (en) | 2010-11-19 | 2012-11-27 | Kensey Nash Corporation | Centrifuge method and apparatus |
US8394006B2 (en) | 2010-11-19 | 2013-03-12 | Kensey Nash Corporation | Centrifuge |
US8870733B2 (en) | 2010-11-19 | 2014-10-28 | Kensey Nash Corporation | Centrifuge |
US8469871B2 (en) | 2010-11-19 | 2013-06-25 | Kensey Nash Corporation | Centrifuge |
US9011684B2 (en) | 2011-03-07 | 2015-04-21 | Spinesmith Holdings, Llc | Fluid concentrator with removable cartridge |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
US20140364833A1 (en) * | 2011-05-19 | 2014-12-11 | Intermountain Invention Management, Llc | Fetal blood recovery systems and methods |
CL2011001870A1 (en) | 2011-08-03 | 2012-01-27 | U Tecnica Federico Santa Maria 28 71% | Process of preparing an autologous or compatible blood fibrin gel for cell proliferation and vehiculization; compatible fibrin or blood gel; use of compatible fibrin or blood gel for surgical use. |
EP2574350A1 (en) | 2011-09-29 | 2013-04-03 | Biorigen S.r.l | Medical uses of lyophilized polymeric membranes containing blood derivatives |
CN103191016B (en) * | 2012-01-09 | 2015-07-29 | 金卫医疗科技(上海)有限公司 | The soft bag of separation of blood plasma DNA purity is improved when a kind of blood is continuously separated |
US9327296B2 (en) | 2012-01-27 | 2016-05-03 | Fenwal, Inc. | Fluid separation chambers for fluid processing systems |
US20130202675A1 (en) | 2012-02-03 | 2013-08-08 | Dynasil Biomedical Corporation | Systems and methods for the fabrication of tissue patches |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
WO2014052496A1 (en) | 2012-09-25 | 2014-04-03 | Stem Cell Partners Llc | Method and apparatus for preparing single donor thrombin serum |
US9414752B2 (en) | 2012-11-09 | 2016-08-16 | Elwha Llc | Embolism deflector |
US8803090B2 (en) | 2012-11-09 | 2014-08-12 | Fenwal, Inc. | Citrate detector for blood processing system |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
US20140209589A1 (en) * | 2013-01-30 | 2014-07-31 | Illinois Tool Works Lnc. | Guided component extraction system and method |
AU2014216415B2 (en) | 2013-02-12 | 2016-12-15 | Lacerta Technologies Inc. | Serum fraction of platelet-rich fibrin |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
KR101416481B1 (en) | 2013-06-04 | 2014-07-14 | 김홍 | Method for extractioning and cutting platelet of platelet rich fibrin included high-concentration platelet |
US20140356893A1 (en) | 2013-06-04 | 2014-12-04 | Allan Mishra | Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation |
US20160263193A1 (en) * | 2013-11-14 | 2016-09-15 | Nte-Sener Healthcare, S.A. | Method for obtaining a cytokine-rich composition and composition obtained by means of this method |
KR102502975B1 (en) | 2014-01-31 | 2023-02-23 | 디에스엠 아이피 어셋츠 비.브이. | Adipose tissue centrifuge and method of use |
IL231230A0 (en) * | 2014-02-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Fibrinogen formulation |
US10226566B2 (en) * | 2014-04-23 | 2019-03-12 | Genadyne Biotechnologies, Inc. | System and process for removing bodily fluids from a body opening |
US9550028B2 (en) | 2014-05-06 | 2017-01-24 | Biomet Biologics, LLC. | Single step desiccating bead-in-syringe concentrating device |
RU2572447C2 (en) * | 2014-05-22 | 2016-01-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ГБОУ ВПО ВолгГМУ МЗ РФ | Method of treating knee osteoarthrosis |
CN104231066B (en) * | 2014-10-14 | 2017-04-12 | 刘建麟 | Preparation and application method of platelet-derived growth factors for skin beauty |
DE202015009321U1 (en) | 2015-01-22 | 2017-04-19 | The Regents Of The University Of California | Compositions for separating platelet-rich plasma |
ES2671747T3 (en) | 2015-01-22 | 2018-06-08 | The Regents Of The University Of California | Compositions and methods for separation of platelet rich plasma |
BR112017015758A2 (en) * | 2015-01-22 | 2018-03-27 | Univ California | bone marrow and platelet-rich plasma cell separation and removal methods and devices |
JP6629874B2 (en) * | 2015-03-04 | 2020-01-15 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Acoustic radiation force imaging |
US9713810B2 (en) | 2015-03-30 | 2017-07-25 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
US9757721B2 (en) | 2015-05-11 | 2017-09-12 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
EP3124063B1 (en) | 2015-07-29 | 2019-04-10 | Fenwal, Inc. | Five-port blood separation chamber and methods of using the same |
US10588998B2 (en) | 2015-08-07 | 2020-03-17 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
WO2017046809A1 (en) * | 2015-09-20 | 2017-03-23 | Ariel-University Research And Development Company Ltd. | Anti-hemorrhaging compositions |
US20180311404A1 (en) * | 2015-10-27 | 2018-11-01 | Hélio Nogueira da SILVA JUNIOR | Device for preparing a biological wound dressing made of autologous fibrin |
WO2017156379A2 (en) | 2016-03-10 | 2017-09-14 | Arthrex, Inc. | Systems and methods for preparing protein enhanced serums |
AU2017230806B2 (en) | 2016-03-10 | 2021-06-24 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
CN108187780A (en) * | 2017-12-21 | 2018-06-22 | 梁林燕 | A kind of blood platelet is preserved with medical treatment concussion storing unit |
EP3787645A4 (en) * | 2018-05-02 | 2022-06-01 | Ortheus, Inc. | Systems and methods for local modulation of wnt signaling |
GB2579630A (en) * | 2018-12-07 | 2020-07-01 | Biotherapy Services Ltd | Methods and compositions |
CN110660303A (en) * | 2019-08-26 | 2020-01-07 | 东北师范大学 | Method for manufacturing artificial ear of animal specimen |
IT201900015707A1 (en) * | 2019-09-05 | 2021-03-05 | Emotec Srl | "MEDICAL DEVICE AND APPARATUS FOR THE PRODUCTION, WITH CLOSED CIRCUIT, OF PLASMA RICH IN PLATES AND DERIVATIVES, FOR NON-TRANSFUSIONAL USE" |
WO2021176457A1 (en) | 2020-03-05 | 2021-09-10 | Ariel Scientific Innovations Ltd. | Anti-hemorrhaging compositions |
ES2957484A1 (en) * | 2022-06-07 | 2024-01-19 | Santxa Res S L U | Fibrin gel and method of obtaining it (Machine-translation by Google Translate, not legally binding) |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4627897A (en) * | 1984-01-19 | 1986-12-09 | Hoechst Aktiengesellschaft | Process for the electrolysis of liquid electrolytes using film flow techniques |
US4874368A (en) * | 1988-07-25 | 1989-10-17 | Micromedics, Inc. | Fibrin glue delivery system |
US5089415A (en) * | 1990-09-17 | 1992-02-18 | International Technidyne Corp. | Method for clotting heparized blood by the addition of protamine, thrombin and snake venom |
US5104375A (en) * | 1989-10-16 | 1992-04-14 | Johnson & Johnson Medical, Inc. | Locking holder for a pair of syringes and method of use |
US5165938A (en) * | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
US5185001A (en) * | 1990-01-18 | 1993-02-09 | The Research Foundation Of State University Of New York | Method of preparing autologous plasma fibrin and application apparatus therefor |
US5354682A (en) * | 1990-02-20 | 1994-10-11 | Baxter International Inc. | Viral-safe purified human thrombin |
US5391380A (en) * | 1991-07-22 | 1995-02-21 | Helena Laboratories, Corp. | Thromboplastin extract, reagent, and preparation thereof |
US5474540A (en) * | 1994-03-25 | 1995-12-12 | Micromedics, Inc. | Fluid separation control attachment for physiologic glue applicator |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5585007A (en) * | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
US5589462A (en) * | 1992-09-30 | 1996-12-31 | Inoteb | Method of preparing a biological adhesive enriched with platelet factors, and application |
US5607694A (en) * | 1994-02-17 | 1997-03-04 | New York Blood Center, Inc. | Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use |
US5643192A (en) * | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US5738784A (en) * | 1994-12-02 | 1998-04-14 | E.R. Squibb & Sons, Inc. | Device for separating a blood component from blood or plasma |
US5739288A (en) * | 1992-10-08 | 1998-04-14 | Bristol-Myers Squibb Company | Fibrin sealant compositions |
US5795571A (en) * | 1992-06-24 | 1998-08-18 | Bristol-Myers Squibb Company | Composition containing autologous thrombin blood fraction for use in a medical procedure |
US6132396A (en) * | 1996-02-06 | 2000-10-17 | Plasmaseal Llc | Apparatus for applying tissue sealant |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6197194B1 (en) * | 1995-03-24 | 2001-03-06 | Elaine Whitmore | Single use system for preparing autologous plasma and fibrin gel |
US6200587B1 (en) * | 1998-05-15 | 2001-03-13 | Hogy Medical Co., Ltd. | Tissue sealant containing fibrinogen, thrombin and carboxymethyl cellulose or salt thereof |
US20020004038A1 (en) * | 1996-04-30 | 2002-01-10 | Baugh Robert F. | Autologous platelet gel spray delivery system |
US6444228B1 (en) * | 1996-04-30 | 2002-09-03 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US6472162B1 (en) * | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
US6942880B1 (en) * | 2001-04-09 | 2005-09-13 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US713017A (en) | 1901-03-08 | 1902-11-04 | Walter H Pumphrey | Syringe. |
US1614532A (en) | 1921-02-26 | 1927-01-18 | Joseph Reed Littell | Means for applying liquid medicaments under pressure action |
US2533004A (en) | 1943-10-27 | 1950-12-05 | John D Ferry | Fibrin clots and methods for preparing the same |
FR1051010A (en) | 1952-02-21 | 1954-01-12 | New syringe for injection | |
US2747936A (en) | 1953-11-17 | 1956-05-29 | Spraying Systems Co | Whirl spray nozzle |
US3223083A (en) | 1960-09-09 | 1965-12-14 | President And Directors Of Geo | Method for adhesively securing together skin and other soft tissue and bone |
US3179107A (en) | 1962-11-21 | 1965-04-20 | Becton Dickinson Co | Hypodermic unit with an improved mounting for a replaceable needle assembly |
US3269389A (en) | 1963-03-11 | 1966-08-30 | Bernard L Meurer | Compartmental dispensing container for nose and throat preparations |
US3236457A (en) | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3467096A (en) | 1966-04-12 | 1969-09-16 | Ferrell S Horn | Multiple hypodermic syringe arrangement |
US3416737A (en) | 1967-04-05 | 1968-12-17 | Risdon Mfg Co | Mechanical break-up spray button |
US3557787A (en) | 1968-05-28 | 1971-01-26 | Milton J Cohen | Disposable syringe |
US3494359A (en) | 1969-03-17 | 1970-02-10 | Silver Jules | Two compartment syringe with a single barrel |
US3945574A (en) | 1972-07-24 | 1976-03-23 | Polnauer Frederick F | Dual orifice spray nozzle using two swirl chambers |
US3828980A (en) | 1972-11-06 | 1974-08-13 | Chem Dev Corp | Dispenser for precisely metered dispensing of viscous fluids |
US3814516A (en) * | 1973-05-07 | 1974-06-04 | Xerox Corp | Humidity compensated control device |
US3942725A (en) | 1975-01-03 | 1976-03-09 | Green Edward | Sprayhead for swirling spray |
AT341649B (en) | 1975-08-07 | 1978-02-27 | Immuno Ag | INJECTION SYRINGE |
US4040420A (en) | 1976-04-22 | 1977-08-09 | General Dynamics | Packaging and dispensing kit |
US4109653A (en) | 1977-02-22 | 1978-08-29 | George Kozam | Successive delivery multiple barrel syringe |
US4265233A (en) | 1978-04-12 | 1981-05-05 | Unitika Ltd. | Material for wound healing |
AT359652B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
AT359653B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
US4374830A (en) | 1979-10-04 | 1983-02-22 | Research Corp. | Platelet aggregating material from equine arterial tissue |
AT366916B (en) | 1980-04-02 | 1982-05-25 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE BASED ON HUMAN OR ANIMAL PROTEINS |
US4369117A (en) * | 1980-05-12 | 1983-01-18 | American Hospital Supply Corporation | Serum separating method and apparatus |
US4363319A (en) | 1980-06-30 | 1982-12-14 | Applied Medical Devices, Inc. | Ready-to-use bandage incorporating a coagulant composition and method of preparing same |
DE3105624A1 (en) | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
ATE20824T1 (en) | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING. |
US4442655A (en) | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
DE3171072D1 (en) | 1981-06-25 | 1985-07-25 | Stroetmann M Serapharm | Enriched plasma derivative for promoting wound sealing and wound covering |
JPS59500340A (en) * | 1982-03-08 | 1984-03-01 | モトロ−ラ・インコ−ポレ−テツド | integrated circuit lead frame |
US4634709A (en) * | 1982-04-15 | 1987-01-06 | Research Corporation | Platelet aggregation inhibitory agents and intermediates therefor |
DK150403C (en) * | 1983-07-15 | 1987-07-13 | Radiometer As | BLOOD SAMPLING EQUIPMENT |
AT379311B (en) | 1984-03-29 | 1985-12-27 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
DE3417757C2 (en) | 1984-05-12 | 1994-11-10 | Lucas Dieter Dr | Hypodermic syringe |
JPS6144825A (en) | 1984-08-09 | 1986-03-04 | Unitika Ltd | Hemostatic agent |
US4627879A (en) | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
EP0189900B1 (en) | 1985-01-29 | 1989-04-05 | Fuji Photo Film Co., Ltd. | Duplex pipette |
US4678470A (en) | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
AT382783B (en) | 1985-06-20 | 1987-04-10 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
US4609371A (en) | 1985-06-24 | 1986-09-02 | Pizzino Joanne L | Dual syringe for either simultaneous or sequential injection of liquids |
US4696812A (en) | 1985-10-28 | 1987-09-29 | Warner-Lambert Company | Thrombin preparations |
DE3614515A1 (en) | 1986-04-29 | 1987-11-05 | Pfeiffer Erich Gmbh & Co Kg | DISCHARGE DEVICE FOR MEDIA |
FR2602089B1 (en) | 1986-07-23 | 1988-10-21 | Radiotechnique Compelec | RETRACTABLE SHORT-CIRCUIT AND USE OF THIS SHORT-CIRCUIT IN A PHOTOELECTRIC TUBE |
US4714457A (en) | 1986-09-15 | 1987-12-22 | Robert Alterbaum | Method and apparatus for use in preparation of fibrinogen from a patient's blood |
US4767416A (en) | 1986-12-01 | 1988-08-30 | Johnson & Johnson Patient Care, Inc. | Spray nozzle for syringe |
US4965203A (en) | 1987-01-28 | 1990-10-23 | Warner-Lambert Company | Purified thrombin preparations |
JPS63243032A (en) | 1987-03-27 | 1988-10-07 | Green Cross Corp:The | Method for heat-treating thrombin |
JPS6440433A (en) | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
US4752466A (en) | 1987-08-31 | 1988-06-21 | Johnson & Johnson Products, Inc. | Thrombin aerosol |
JP2771548B2 (en) * | 1987-09-11 | 1998-07-02 | キヤノン株式会社 | Ink jet recording device |
US4842581A (en) | 1987-09-11 | 1989-06-27 | Davis Richard C | Medical lavage apparatus |
US4978336A (en) | 1987-09-29 | 1990-12-18 | Hemaedics, Inc. | Biological syringe system |
DE3734923C1 (en) | 1987-10-15 | 1989-01-26 | Biotest Pharma Gmbh | Process for the preparation of a sterile plasma protein solution containing fibrinogen and coagulation factor XIII |
US5290552A (en) | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
AT397203B (en) | 1988-05-31 | 1994-02-25 | Immuno Ag | FABRIC ADHESIVE |
US4902281A (en) | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
FR2639958B1 (en) | 1988-12-06 | 1992-08-21 | Lille Transfusion Sanguine | BIOLOGICAL SUPPORT FOR CELL CULTURES CONSISTING OF PLASMATIC PROTEINS COAGULATED BY THROMBIN, ITS USE FOR THE CULTURE OF KERATINOCYTES, THEIR RECOVERY AND THEIR TRANSPORT FOR THERAPEUTIC USE |
DE3843126C3 (en) | 1988-12-22 | 1994-10-06 | Octapharma Ag | Process for the production of a high-purity thrombin concentrate |
US5226877A (en) | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
US5116315A (en) | 1989-10-03 | 1992-05-26 | Hemaedics, Inc. | Biological syringe system |
US4979942A (en) | 1989-10-16 | 1990-12-25 | Johnson & Johnson Medical, Inc. | Two component syringe delivery system |
US5037390A (en) | 1989-12-28 | 1991-08-06 | Kenneth Raines | System and method for mixing parenteral nutrition solutions |
US5318524A (en) | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US5030215A (en) * | 1990-01-03 | 1991-07-09 | Cryolife, Inc. | Preparation of fibrinogen/factor XIII precipitate |
US5219328A (en) | 1990-01-03 | 1993-06-15 | Cryolife, Inc. | Fibrin sealant delivery method |
US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
IE73210B1 (en) | 1990-01-24 | 1997-05-07 | Warner Lambert Co | Process for the production of thrombin and high purity thrombin preparation thereby obtained |
US5089146A (en) * | 1990-02-12 | 1992-02-18 | Miles Inc. | Pre-storage filtration of platelets |
DK119490D0 (en) | 1990-05-14 | 1990-05-14 | Unes As | Apparatus for the preparation of a concentrate of coagulation factors, such as the fibrinogen, from a blood portion |
US6117425A (en) | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5232024A (en) | 1991-05-30 | 1993-08-03 | Eli Williams | Slide-valve manifold |
US5460945A (en) | 1991-05-30 | 1995-10-24 | Center For Blood Research, Inc. | Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response |
FR2679251B1 (en) | 1991-07-18 | 1993-11-12 | Nord Assoc Essor Transfusion San | PROCESS FOR THE PREPARATION OF A HUMAN THROMBIN CONCENTRATE FOR THERAPEUTIC USE. |
DK166691D0 (en) | 1991-09-30 | 1991-09-30 | Unes As | MULTI-COMPONENT PROJECT |
US5607684A (en) * | 1991-10-31 | 1997-03-04 | Micro Flo Company | Manufacture of bait with hot melt binder |
US5368563A (en) | 1991-12-18 | 1994-11-29 | Micromedics, Inc. | Sprayer assembly for physiologic glue |
US5304371A (en) * | 1992-02-14 | 1994-04-19 | Lasys Corporation | Peptide for diagnosing and immunizing against T. cruzi infection |
AT396937B (en) | 1992-04-06 | 1993-12-27 | Immuno Ag | METHOD FOR ACTIVATING BLOOD COagulation FACTORS |
US5443959A (en) | 1992-09-09 | 1995-08-22 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
US5668589A (en) * | 1992-09-11 | 1997-09-16 | Fuji Photo Film Co., Ltd. | Thermal recording device with controller for correcting laser beam intensity |
ES2130412T5 (en) | 1992-09-26 | 2005-03-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | APPLICATOR OF ADHESIVE DESTINED FOR FABRICS. |
US5290259A (en) | 1993-02-18 | 1994-03-01 | Ultradent Products, Inc. | Double syringe delivery system |
US5330974A (en) | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
US5369995A (en) * | 1993-04-21 | 1994-12-06 | Rutgers, The State University Of New Jersey | Humidity sensor |
US5795780A (en) * | 1993-06-23 | 1998-08-18 | Bristol-Myers Squibb Company | Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes |
US5328462A (en) | 1993-09-03 | 1994-07-12 | Ultradent Products, Inc. | Methods and apparatus for mixing and dispensing multi-part compositions |
AT400675B (en) | 1993-10-18 | 1996-02-26 | Immuno Ag | SYRINGE SET FOR STORAGE AND APPLICATION OF A MULTI-COMPONENT MATERIAL, SYRINGE DEVICE AND ACTUATING DEVICE THEREFOR, AND METHOD FOR PRODUCING A FILLED, STERILE SYRINGE DEVICE |
DE69434332T2 (en) * | 1993-11-12 | 2006-02-02 | Gilead Sciences, Inc., Foster City | THROMBIN MUTANTS |
US5578459A (en) | 1993-11-24 | 1996-11-26 | Abbott Laboratories | Method and apparatus for collecting a cell sample from a liquid specimen |
US5411885A (en) | 1993-12-17 | 1995-05-02 | New York Blood Center, Inc. | Methods for tissue embedding and tissue culturing |
US5408381A (en) * | 1994-04-28 | 1995-04-18 | Johnson Service Company | Capacitance humidity sensor |
JPH0858153A (en) * | 1994-08-18 | 1996-03-05 | Fujitsu Ltd | Serial electronic photography device and print adjustment |
US5506127A (en) | 1994-09-21 | 1996-04-09 | Proba; Zbigniew | Therapeutic grade thrombin produced by chromatography |
US5605541A (en) | 1994-12-07 | 1997-02-25 | E. R. Squibb And Sons, Inc. | Fibrin sealant applicatoor |
US5575779A (en) | 1994-12-30 | 1996-11-19 | Namic U.S.A. Corporation | Liquid regulator and method of use |
CA2207992A1 (en) | 1995-01-16 | 1996-07-25 | Genevieve Krack | Self-supporting sheet-like material of cross-linked fibrin for preventing post operative adhesions |
US5614204A (en) | 1995-01-23 | 1997-03-25 | The Regents Of The University Of California | Angiographic vascular occlusion agents and a method for hemostatic occlusion |
JPH11506649A (en) * | 1995-06-06 | 1999-06-15 | クウォンティック バイオメディカル パートナーズ | Wound sealant preparation and application device and method |
US5712421A (en) * | 1996-01-30 | 1998-01-27 | Arizona Instrument Corporation | Moisture analyzer |
EP0885020A1 (en) * | 1996-02-20 | 1998-12-23 | Cohesion Corporation | Tissue sealant compositions and methods of use thereof |
US5759169A (en) | 1996-03-13 | 1998-06-02 | New York Blood Center Inc. | Fibrin sealant glue-gun |
US6189537B1 (en) * | 1996-09-06 | 2001-02-20 | Lifenet | Process for producing osteoinductive bone, and osteoinductive bone produced thereby |
DE69626135T2 (en) | 1996-09-10 | 2003-10-23 | Omrix Biopharmaceuticals Sa Rh | DEVICE FOR APPLICATING A MULTI-COMPONENT LIQUID |
US5975367A (en) | 1996-09-27 | 1999-11-02 | Thermogenesis Corp. | Fibrin glue line and dot dispenser |
US5759171A (en) | 1996-09-27 | 1998-06-02 | Thermogenesis Corp. | Sprayer for fibrin glue |
US6123687A (en) | 1996-10-30 | 2000-09-26 | Cohesion Technologies, Inc. | Cell separation device and metering syringe |
US5844087A (en) | 1996-11-05 | 1998-12-01 | Bayer Corporation | Method and device for delivering fibrin glue |
JP4116083B2 (en) | 1996-11-15 | 2008-07-09 | ブリストル―マイヤーズ スクイブ カンパニー | Apparatus and method for applying a mixture of two or more liquid components to form a biocompatible material |
US5792938A (en) * | 1996-12-13 | 1998-08-11 | Panametrics, Inc. | Humidity sensor with differential thermal detection and method of sensing |
US6783514B2 (en) | 1997-01-31 | 2004-08-31 | United States Surgical Corporation | Fibrin sealant applicator |
US5807344A (en) * | 1997-02-10 | 1998-09-15 | In-X Corporation | Arterial blood gas syringe including filter member |
US5844138A (en) * | 1997-03-07 | 1998-12-01 | Veris Industries, Inc. | Humidity sensor |
ID23908A (en) | 1997-06-05 | 2000-05-25 | Lilly Co Eli | TREATMENT METHOD OF TROMBOSIS DISEASE |
US6055008A (en) * | 1997-07-16 | 2000-04-25 | Phoenix Precision Graphics, Inc. | Electrostatic printer having two-dimensional humidity compensation |
AU9786198A (en) | 1997-10-10 | 1999-05-03 | University Of Virginia | Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids |
US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
US6482223B1 (en) * | 1997-12-16 | 2002-11-19 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
US6159232A (en) * | 1997-12-16 | 2000-12-12 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
CA2315802C (en) | 1997-12-19 | 2007-09-04 | United States Surgical Corporation | Two component dispenser system |
US6030635A (en) * | 1998-02-27 | 2000-02-29 | Musculoskeletal Transplant Foundation | Malleable paste for filling bone defects |
JP2002506038A (en) | 1998-03-10 | 2002-02-26 | バクスター・インターナショナル・インコーポレイテッド | Thrombin preparation and thrombin product and fibrin sealant method using the same |
US6047861A (en) | 1998-04-15 | 2000-04-11 | Vir Engineering, Inc. | Two component fluid dispenser |
AU2763099A (en) | 1998-06-22 | 2000-01-10 | Charles E. Worden | Enriched platelet wound healant |
US6274090B1 (en) * | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US6230543B1 (en) * | 1999-10-21 | 2001-05-15 | Johnson Controls Technology Co. | Humidity detector calibration method |
JP2001161668A (en) * | 1999-12-07 | 2001-06-19 | Terumo Corp | Blood-collecting equipment |
US6605028B2 (en) * | 2001-04-09 | 2003-08-12 | Medtronic, Inc. | Blood centrifuge having integral heating to control cellular component temperature |
US20040120942A1 (en) * | 2002-12-23 | 2004-06-24 | Mcginnis Daniel | Device and process for the preparation of autologous thrombin serum |
-
1999
- 1999-04-19 WO PCT/US1999/008550 patent/WO2000062828A1/en active Application Filing
-
2001
- 2001-04-09 US US09/832,729 patent/US6942639B2/en not_active Expired - Lifetime
- 2001-04-09 US US09/833,234 patent/US6596180B2/en not_active Expired - Lifetime
- 2001-04-09 US US09/832,517 patent/US6719901B2/en not_active Expired - Lifetime
-
2002
- 2002-06-18 US US10/173,839 patent/US6830762B2/en not_active Expired - Lifetime
-
2003
- 2003-12-17 US US10/738,439 patent/US6899813B2/en not_active Expired - Lifetime
-
2004
- 2004-05-18 US US10/848,302 patent/US20040213777A1/en not_active Abandoned
- 2004-12-03 US US11/004,023 patent/US7811607B2/en not_active Expired - Lifetime
-
2005
- 2005-01-27 US US11/044,984 patent/US7838039B2/en not_active Expired - Lifetime
- 2005-02-02 US US11/049,010 patent/US20050170006A1/en not_active Abandoned
- 2005-04-26 US US11/115,076 patent/US7413652B2/en not_active Expired - Lifetime
- 2005-05-02 US US11/120,305 patent/US7934603B2/en not_active Expired - Lifetime
- 2005-06-23 US US11/159,482 patent/US8303993B2/en not_active Expired - Lifetime
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4627897A (en) * | 1984-01-19 | 1986-12-09 | Hoechst Aktiengesellschaft | Process for the electrolysis of liquid electrolytes using film flow techniques |
US5165938A (en) * | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
US4874368A (en) * | 1988-07-25 | 1989-10-17 | Micromedics, Inc. | Fibrin glue delivery system |
US5104375A (en) * | 1989-10-16 | 1992-04-14 | Johnson & Johnson Medical, Inc. | Locking holder for a pair of syringes and method of use |
US5185001A (en) * | 1990-01-18 | 1993-02-09 | The Research Foundation Of State University Of New York | Method of preparing autologous plasma fibrin and application apparatus therefor |
US5354682A (en) * | 1990-02-20 | 1994-10-11 | Baxter International Inc. | Viral-safe purified human thrombin |
US5089415A (en) * | 1990-09-17 | 1992-02-18 | International Technidyne Corp. | Method for clotting heparized blood by the addition of protamine, thrombin and snake venom |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5391380A (en) * | 1991-07-22 | 1995-02-21 | Helena Laboratories, Corp. | Thromboplastin extract, reagent, and preparation thereof |
US5795571A (en) * | 1992-06-24 | 1998-08-18 | Bristol-Myers Squibb Company | Composition containing autologous thrombin blood fraction for use in a medical procedure |
US5589462A (en) * | 1992-09-30 | 1996-12-31 | Inoteb | Method of preparing a biological adhesive enriched with platelet factors, and application |
US5773418A (en) * | 1992-10-08 | 1998-06-30 | Bristol-Myers Squibb Company | Fibrin sealant compositions and methods for utilizing same |
US5739288A (en) * | 1992-10-08 | 1998-04-14 | Bristol-Myers Squibb Company | Fibrin sealant compositions |
US5750657A (en) * | 1992-10-08 | 1998-05-12 | Bristol-Myers Squibb Company | Methods and compositions using fibrin monomer to make a fibrin sealant |
US5607694A (en) * | 1994-02-17 | 1997-03-04 | New York Blood Center, Inc. | Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use |
US5474540A (en) * | 1994-03-25 | 1995-12-12 | Micromedics, Inc. | Fluid separation control attachment for physiologic glue applicator |
US5738784A (en) * | 1994-12-02 | 1998-04-14 | E.R. Squibb & Sons, Inc. | Device for separating a blood component from blood or plasma |
US5585007A (en) * | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
US6214338B1 (en) * | 1994-12-07 | 2001-04-10 | Plasmaseal Llc | Plasma concentrate and method of processing blood for same |
US5788662A (en) * | 1994-12-07 | 1998-08-04 | Plasmaseal Llc | Methods for making concentrated plasma and/or tissue sealant |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US5733545A (en) * | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US6197194B1 (en) * | 1995-03-24 | 2001-03-06 | Elaine Whitmore | Single use system for preparing autologous plasma and fibrin gel |
US5643192A (en) * | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
US6132396A (en) * | 1996-02-06 | 2000-10-17 | Plasmaseal Llc | Apparatus for applying tissue sealant |
US20050152886A1 (en) * | 1996-04-30 | 2005-07-14 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US6899813B2 (en) * | 1996-04-30 | 2005-05-31 | Medtronic, Inc. | Method for the production of a blood component composition |
US6444228B1 (en) * | 1996-04-30 | 2002-09-03 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US20050252867A1 (en) * | 1996-04-30 | 2005-11-17 | Medtronic, Inc. | Methods of applying a biological composition to an individual |
US6596180B2 (en) * | 1996-04-30 | 2003-07-22 | Medtronic, Inc. | System and method for the production of autologous platelet gel |
US6719901B2 (en) * | 1996-04-30 | 2004-04-13 | Medtronic, Inc. | System for the production of an autologous thrombin |
US20040132003A1 (en) * | 1996-04-30 | 2004-07-08 | Dolecek Victor D. | Method for the production of a blood component composition |
US20040213777A1 (en) * | 1996-04-30 | 2004-10-28 | Baugh Robert F. | Methods of applying a biological composition to an individual |
US6830762B2 (en) * | 1996-04-30 | 2004-12-14 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US20020004038A1 (en) * | 1996-04-30 | 2002-01-10 | Baugh Robert F. | Autologous platelet gel spray delivery system |
US20050129674A1 (en) * | 1996-04-30 | 2005-06-16 | Medtronic, Inc. | Methods of applying a biological composition to an individual |
US20050236325A1 (en) * | 1996-04-30 | 2005-10-27 | Medtronic, Inc. | Method for the production of a blood component composition |
US20050209081A1 (en) * | 1996-04-30 | 2005-09-22 | Medtronic, Inc. | Autologous platelet gel spray delivery system |
US6942639B2 (en) * | 1996-04-30 | 2005-09-13 | Medtronic, Inc. | Autologous platelet gel delivery system |
US6200587B1 (en) * | 1998-05-15 | 2001-03-13 | Hogy Medical Co., Ltd. | Tissue sealant containing fibrinogen, thrombin and carboxymethyl cellulose or salt thereof |
US6472162B1 (en) * | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
US6942880B1 (en) * | 2001-04-09 | 2005-09-13 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7811607B2 (en) | 1996-04-30 | 2010-10-12 | Arteriocyte Medical Systems, Inc. | Autologous fibrin sealant and method for making the same |
US20090026123A1 (en) * | 1996-04-30 | 2009-01-29 | Dolecek Victor D | System for the production of autologus platelet gel useful for the delivery of medicinal and genetic agents |
US20050152886A1 (en) * | 1996-04-30 | 2005-07-14 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
US20050236325A1 (en) * | 1996-04-30 | 2005-10-27 | Medtronic, Inc. | Method for the production of a blood component composition |
US20050252867A1 (en) * | 1996-04-30 | 2005-11-17 | Medtronic, Inc. | Methods of applying a biological composition to an individual |
US8303993B2 (en) | 1996-04-30 | 2012-11-06 | Ateriocyte Medical Systems, Inc. | Methods of applying a biological composition to an individual |
US20050129674A1 (en) * | 1996-04-30 | 2005-06-16 | Medtronic, Inc. | Methods of applying a biological composition to an individual |
US7838039B2 (en) | 1996-04-30 | 2010-11-23 | Arteriocyte Medical Systems, Inc. | Autologous fibrin sealant and method for making same |
US20040213777A1 (en) * | 1996-04-30 | 2004-10-28 | Baugh Robert F. | Methods of applying a biological composition to an individual |
US20070172472A1 (en) * | 2005-06-23 | 2007-07-26 | Asha Nayak | Methods and Systems for Treating Injured Cardiac Tissue |
US20070093748A1 (en) * | 2005-06-23 | 2007-04-26 | Medtronic Vascular, Inc. | Methods and systems for treating injured cardiac tissue |
US20080044852A1 (en) * | 2006-04-26 | 2008-02-21 | Tessy Kanayinkal | Compositions and methods of preparation thereof |
US9096839B2 (en) | 2006-04-26 | 2015-08-04 | Arteriocyte Medical Systems, Inc. | Compositions and methods of preparation thereof |
US8586324B2 (en) | 2011-08-15 | 2013-11-19 | Biomet Biologics, Llc | Method and apparatus to create autologous clotting serum |
US9815038B2 (en) | 2011-08-15 | 2017-11-14 | Biomet Biologics, Llc | Method and apparatus to create autologous clotting serum |
Also Published As
Publication number | Publication date |
---|---|
US20050129674A1 (en) | 2005-06-16 |
US7838039B2 (en) | 2010-11-23 |
US20050209081A1 (en) | 2005-09-22 |
US20020004038A1 (en) | 2002-01-10 |
US6899813B2 (en) | 2005-05-31 |
WO2000062828A1 (en) | 2000-10-26 |
US8303993B2 (en) | 2012-11-06 |
US20040132003A1 (en) | 2004-07-08 |
US6719901B2 (en) | 2004-04-13 |
US20020022213A1 (en) | 2002-02-21 |
US7934603B2 (en) | 2011-05-03 |
US7811607B2 (en) | 2010-10-12 |
US20050236325A1 (en) | 2005-10-27 |
US20050252867A1 (en) | 2005-11-17 |
US20040213777A1 (en) | 2004-10-28 |
US6596180B2 (en) | 2003-07-22 |
US6830762B2 (en) | 2004-12-14 |
US6942639B2 (en) | 2005-09-13 |
US7413652B2 (en) | 2008-08-19 |
US20020159985A1 (en) | 2002-10-31 |
US20010055621A1 (en) | 2001-12-27 |
US20050152886A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7838039B2 (en) | Autologous fibrin sealant and method for making same | |
US6444228B1 (en) | Autologous fibrin sealant and method for making the same | |
JP2987207B2 (en) | Preparation method of bioadhesive rich in platelet factor and its application | |
KR100411438B1 (en) | Plasma Concentrates and Tissue Suture Compositions | |
US5733545A (en) | Platelet glue wound sealant | |
US5605887A (en) | Therapeutic fibrinogen compositions | |
Thorn et al. | Autologous fibrin glue with growth factors in reconstructive maxillofacial surgery | |
JP4860857B2 (en) | Self-derived thrombin | |
Reiss et al. | Autologous fibrin glue: production and clinical use | |
JP2003517272A (en) | Apparatus and method for preparing stable, long-term thrombin from plasma, and thrombin formed thereby | |
JPH05286999A (en) | Stable fibrinogen solution | |
Fattahi et al. | Clinical applications of fibrin sealants | |
US8124075B2 (en) | Enhanced biological autologous tissue adhesive composition and methods of preparation and use | |
US20060261014A1 (en) | Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma | |
WO2010042741A1 (en) | Methods of making concentrated fibrinogen- and platelet containing compositions | |
JP4493857B2 (en) | Autograft fibrin sealant and method of making the same | |
CA2306629A1 (en) | Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma | |
Stemberger et al. | Characterization of biomaterials for tissue repair | |
Trowbridge | Fibrin Glue and Platelet Gel | |
Alston | Autologous fibrinogen purification and concentration for use in fibrin sealant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARTERIOCYTE MEDICAL SYSTEMS, INC., OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDTRONIC, INC.;REEL/FRAME:020362/0735 Effective date: 20071024 |
|
AS | Assignment |
Owner name: MEDTRONIC, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAUGH, ROBERT F.;LIM, LISA M.;RIVERA, JOHN G.;AND OTHERS;REEL/FRAME:020652/0391 Effective date: 19980420 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |
|
AS | Assignment |
Owner name: COMERICA BANK, MICHIGAN Free format text: SECURITY INTEREST;ASSIGNOR:ARTERIOCYTE MEDICAL SYSTEMS, INC.;REEL/FRAME:034170/0303 Effective date: 20141024 |
|
AS | Assignment |
Owner name: ARTERIOCYTE MEDICAL SYSTEMS MANUFACTURING OF MASSA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:COMERICA BANK;REEL/FRAME:038381/0895 Effective date: 20160401 |
|
AS | Assignment |
Owner name: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT, ILLINO Free format text: SECURITY INTEREST;ASSIGNOR:ARTERIOCYTE MEDICAL SYSTEMS, INC.;REEL/FRAME:042727/0600 Effective date: 20170615 |
|
AS | Assignment |
Owner name: ISTO TECHNOLOGIES II, LLC, MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:TWIN BROOK CAPITAL PARTNERS, LLC;REEL/FRAME:065269/0604 Effective date: 20231016 |